UMP Healthcare : INTERIM REPORT 2020/2021

CONTENTS 目錄

• 2 Corporate Information ʮ̡༟ࣘ

• 4 Management Discussion and Analysis ၍ଣᄴীሞʿʱؓ

• 19 Corporate Governance Highlights

  Άุ၍ط࿜ࠅ

• 21 Other Information

  Չ˼༟ࣘ

• 33 Condensed Consolidated Statement of Profit or Loss ᔊ׼ၝΥฦूڌ

  • 35 Condensed Consolidated Statement of Financial Position ᔊ׼ၝΥৌਕًرڌ

  • 37 Condensed Consolidated Statement of Changes in Equity ᔊ׼ၝΥᛆूᜊਗڌ

  • 38 Condensed Consolidated Statement of Cash Flows ᔊ׼ၝΥତږݴඎڌ

  • 40 Notes to the Condensed

    Consolidated Interim Financial

    Statements ᔊ׼ၝΥʕಂৌਕజڌڝൗ

• 34 Condensed Consolidated Statement of Comprehensive Income ᔊ׼ၝΥΌࠦϗɝڌ

• 67 Glossary ൚ค

Corporate Information 公司資料

BUSINESS OVERVIEW AND OUTLOOK

Healthcare is not only a cornerstone to the overall well-being of citizens but it is also the foundation of economic and social development. In the last six months, COVID-19 continued to pose unprecedented risks and opportunities for our Group. As the third and fourth waves of COVID-19 hit the shores of Hong Kong, widespread fear of the contagion as well as sustained economic volatility ensued. Against this backdrop, however, our Group continued to record steady revenue performance in the six months ended 31 December 2020, which testified to our reputation as one of the premier medical service providers in Hong Kong. Further, the perceptible shock of COVID-19 and the resulting social distancing protocols validated our continued investment in technology. We believe COVID-19 has expedited public reception toward medical technology and we are poised to use it as an enabler to enhance our service quality and reach.

業務回顧及展望

ᔼᐕڭ਄ʔఊ݊ɛ͏၅߀ٙᇂͩdՉһ݊຾ ᏶ʿٟึ೯࢝ٙਿͩfཀ̘ʬࡈ˜dอۨڿ ًषݭᘱᚃމ͉ණྠ੭Ըۃה͊ԈٙΚၾ ዚfᎇഹ࠰ಥᖑ೯ୋɧʿୋ̬تอۨڿًष ݭޥઋd࿁ޥઋٙࢵฑίٟึᇶַdՉ຾᏶ ਗᐗ͵౨ʘʔ̘f್ϾdίνϤѢྤʕd͉ ණྠ׵࿚Ї 2020ϋ12˜31 ˚˟ʬࡈ˜ᘱᚃ ፽੻ᖢ਄ٙϗɝุᐶdᗇ׼͉ණྠᆽ݊࠰ಥ ᎴӸٙᔼᐕ؂ਕԶᏐ٫ʘɓfϤ̮dอۨڿ ًषݭה੭ԸٙቤᐗʿΪϤྼ݄ٟٙਜཞᕎ ણ݄dΙᗇҢࡁܵᚃҳ༟߅ҦϞଣfҢࡁ޴ ڦdอۨڿًषݭʊ౤৷౷ᖯɽ଺࿁ᔼᐕҦ ஔٙટա೻ܓdϾҢࡁ͵๟௪˸Ϥ౤ʺҢࡁ ٙ؂ਕሯ९ʿᓒɽ̹ఙf

In Hong Kong, despite the impact of the contagion, we were able to capitalize on our extensive business network to provide uninterrupted offline clinical services to outpatients as well as policyholders of corporates and insurance companies at the primary care entry level. Our commitment to communal healthcare extended to provide year-round, all-encompassing medical services in areas such as general and specialist services, regular health check-ups, medical imaging and laboratory services, dental services, physiotherapy clinics and cosmetic dermatology centre. We firmly believe that our core strength in Hong Kong lies in our dynamic, full-service ecosystem that can fulfill our clients' shifting demand.

׵࠰ಥdኋ၍աՑޥઋᅂᚤdઓҢࡁʥঐл ͜ҢࡁٙᄿɽุਕၣഖdΣژൢषɛ˸ʿΆ ุձڭᎈʮ̡ٙڭఊܵϞɛ౤Զೌගᓙٙ ᇞɨਿᄴᔼᐕژൢ؂ਕfҢࡁ࿁Ό͏ᔼᐕٙ וፕʊᓒ࢝ЇΌϋೌ;ٙΌ˙ࠦᔼᐕ؂ਕd Էν౷ஷ߅ձਖ਼߅؂ਕe֛ಂ਄ੰᏨݟeᔼ ኪᅂ྅ʿʷ᜕؂ਕe˫߅؂ਕeيଣطᐕൢ הʿߕ࢙ͤᇮ߅ʕːfҢࡁଉڦdҢࡁ׵࠰ ಥٙࣨːᎴැί׵ঐ੄တԑ܄˒ʔᓙᜊʷც ӋeਗɢတޮϾ଄ႊΌ˙З؂ਕٙ͛࿒ਸ਼f

Our competitive differentiation shone through in the time of COVID-19. When social distancing in Hong Kong became commonplace, our clients and their employees relied more than ever on our continuous, innovative corporate healthcare solutions and tailor-made third-party administration services such as 24/7 customer care hotline to address their rising needs. Our agile business models also gave us the flexibility to seize online business opportunities while contributing to the containment of the COVID-19 impact as a socially responsible healthcare group. As concerns over the rising COVID-19 rose to an alarming level, we expanded our online products offering to include same-day-delivery of COVID-19 screening test kits. We believe our swift response and expansion in time of crisis are testament to our professionalism and our belief in the growth prospects within the region.

ίอۨڿًषݭޥઋಂගdҢࡁჯ΋Ν኎ٙ ᘩنᎴැᜑᚣೌ፲f຅ٟʹ൷ᕎણ݄ʊϓމ ࠰ಥٟึ੬࿒ʘࣛdҢࡁٙ܄˒ʿՉࡰʈ޴ ༰˸ֻ΂ОࣛගɰһԱࠠҢࡁʔᓙ௴อٙΆ ุᔼᐕ༆Ӕ˙ࣩձ֛Փٙୋɧ˙၍ଣ؂ਕd νீཀ24ʃࣛ܄˒؂ਕਖ਼ᇞတԑ˼ࡁʔᓙᄣ ̋ٙცࠅfᏐԫԘઽุٙਕᅼόɰᜫҢࡁᜳ ݺҪ౥ᇞɪਠዚdΝࣛЪމɓගɢБٟึப ΂ٙᔼᐕණྠdމ༿ՓอۨڿًषݭᅂᚤЪ ্̈ᘠfอۨڿًषݭޥઋһᒈᘌࢡʘყd ɽ଺ᅊᙰᗭеdϞԈʿϤdҢࡁᓒɽəᇞɪ ପۜٙᇍᖚdܼ̍у˚৔჈อۨڿًषݭጜ ݟ಻༊̍fҢࡁ׵Κዚʘʕ຅ዚͭᓙԨᓒɽ ஝ᅼd޴ڦʊԑᗇҢࡁٙਖ਼ุၚग़ʿ࿁ਜʫ ೯࢝ۃ౻ٙڦːf

In the last six months, while our offline clinics uncharacteristically dropped in patient volume during the COVID-19 outbreak, our online consultation services have garnered significant interest from our existing and new customers as Hong Kong citizens became wary of going to public places. The abrupt shift in market sentiment justifies our timely decision to augment our offline network with an expanding online presence. To further improve our digital footprint, our information technology teams in Hong Kong and China have been working around the clock to refine our web-and-app-based telemedicine platforms in both regions. As an indication to our adaptability to the evolving needs of our customers, during the peak of the COVID-19 pandemic, we leveraged on technology to overcome the barriers of social distancing and provide cutting-edge, web-based teleconsultation to multiple Hong Kong-based conglomerates, reputable insurance companies and private clients.

ཀ̘ʬࡈ˜d͟׵࠰ಥ͏଺ᒒеۃֻʮ଺ఙ הdҢࡁٙྼ᜗ൢה׵อۨڿًषݭᖑ೯ಂ ගٙઃ٫ఱൢɛϣΪϾಯˇdઋرၾཀ̘ࠕ ್ʔΝdШҢࡁٙᇞɪᏐൢ؂ਕۆ੻ՑତϞ ʿอ܄˒ٙڡຕfࠦ࿁̹ఙઋၫᒓᜊdҢࡁ ͵ΪࣛՓ֝Ъ̈Ӕ֛d˸ʔᓙѯɽٙᇞɪุ ਕԸᄣ੶ᇞɨၣഖfމəආɓӉ౤ʺҢࡁٙ ᇞɪุਕوྡdҢࡁ׵࠰ಥʿʕ਷ٙ༟ৃ߅ Ҧྠඟɓٜ˚˸ᘱցʈЪd˸ҁഛவՇࡈή ਜٙჃ೻ᔼᐕၣഖʿᏐ̨̻͜fҢࡁ༶͜߅ Ҧ͂ॎٟึ൷ᕎણ݄ிϓٙཞჟdΣ࠰ಥε ගၝΥΆุeڦᚑԄλٙ࠰ಥڭᎈʮ̡ձӷ ɛ܄˒౤Զ࿃อٙၣɪჃ೻Ꮠൢ؂ਕdΙᗇ Ңࡁঐ੄ቇᏐʔᓙᜊʷٙ܄˒ცӋf

We believe the future delivery of healthcare is hinged upon finding an optimal balance between online and offline service platforms. In the coming future, we will continue to invest in technology to connect patients to the most appropriate care medium to make healthcare more accessible and affordable to the general public. Capitalizing on our vast customer base, in-house medical teams, and proprietary technology, we will continue to deepen the integration between online and offline healthcare services.

Ңࡁ޴ڦd͊Ըٙᔼᐕ؂ਕ՟Ӕ׵ᇞɪၾᇞ ɨ؂ਕ̨̻ʘගٙ௰Գ̻ፅfҢࡁ˚ܝਗ਼ᘱ ᚃҳ༟׵߅Ҧdމઃ٫ҬՑ௰Υቇٙ؂ਕద ʧdᜫ౷ᖯɽ଺ᐏ੻һ̙ʿ˲̙ࠋዄٙᔼᐕ ؂ਕfԱቦᕼɽٙ܄˒໊eʫ௅ᔼᐕྠඟʿ ਖ਼ϞҦஔdҢࡁਗ਼ᘱᚃଉʷᇞɪၾᇞɨᔼᐕ ؂ਕፄΥf

Our focus on providing quality health services expands beyond the borders of Hong Kong. Currently, our Greater China network boasts more than 800 self-owned and affiliated medical service points across Hong Kong, Macau, Beijing, Tianjin, Shanghai, as well as other major cities in the GBA including Guangzhou, Shenzhen, Zhuhai, Zhongshan, Dongguan and Foshan. Further, our remote consultation platform in China serves as a crucial portal to connect family doctors to deliver on-demand, face-to-face online consultations to insured policyholders.

Ңࡁਖ਼ء׵౤ԶᎴሯᔼᐕ؂ਕdԨן࢝Ї ࠰ಥ˸̮fͦۃdҢࡁٙɽʕശਜၣഖѬኹ ൴ཀ 800 ࡈІᐄʿڝ᙮ᔼᐕ؂ਕᓃdཁ̺࠰ ಥeዦ ژȅ ԯe˂ ݵeɪ ऎd˸ ʿ ᄿ ψe ଉέeमऎeʕʆe؇୷ʿНʆഃɽᝄਜՉ ˼˴ࠅ̹۬fϤ̮dҢࡁ׵ʕ਷ٙჃ೻Ꮠൢ ̨̻ɗஹટ࢕ࢬᔼ͛ٙࠠࠅژ˒d˸ܲცࠅ މڭఊܵϞɛ౤Զࠦ࿁ࠦٙᇞɪᏐൢf

In recent years, consistent with the Chinese government's emphasis on improving the quality of primary care, the Group has broadened the breadth and depth of our family doctor and nurse training through our revered GOLDTM training and GOLDTM-EN training programmes, respectively. Despite the restrictions placed upon cross-border traveling during COVID-19, we continued to administer a combination of online and offline trainings to our students in the Mainland to optimum effect.

ڐϋdމৣΥʕ਷ִ݁ءࠠ౤৷ਿᄴᔼᐕ؂ ਕሯ९d͉ණྠʱйீཀ௪աႩ̙ٙGOLD™ ږ೐੃৅ሙ೻ʿGOLD™-ENږ೐ᚐɻ੃৅ሙ ೻dᓒɽ࢕ࢬᔼ͛ʿᚐɻ੃৅ሙ೻ٙᄿܓʿ ଉܓfኋ၍༨ྤ༷ࣚ׵อۨڿًषݭໍ߿ಂ ගաՑࠢՓdઓҢࡁᘱᚃމʫήኪࡰ౤Զᇞ ɪᇞɨԨБٙ੃৅d˸༺Ց௰Գࣖ؈f

We undertook the mission of fostering efficient collaboration between well-trained doctors and patients in a bid to build a scalable but agile medical service platform. Our unique GOLDTM and GOLDTM-EN programmes have delivered trainings to almost 1,000 doctors and nurses cumulatively in Mainland China, with a focus on GBA. Our clinic network with various regional and local governments consists of 45 established PPP with over 40 others scheduled to be built. Our expansion even in the time of global economic uncertainty made us one of the largest outpatient clinic networks in the GBA. We will deploy more GOLDTM-trained doctors and GOLDTM-EN-trained nurses to our existing and new PPP or to our virtual care platform down the road to enhance the standard and reach of medical services in GBA.

Innovation is the key to sustained success especially in a vast and growing market such as Mainland China. Our Group has made tremendous headway in being a market-leading trendsetter. In August 2020, we have officially launched our Internet hospital business. As the only Hong Kong-based healthcare platform with an Internet hospital license, we will continue to provide patients and Mainland residents with licensed telemedicine services through our network of highly qualified doctors and the development of strategic partnerships with new and existing specialist group.

ҢࡁٙԴն݊׵ᅃஔԨᎴٙᔼ͛ၾઃ٫ʘග ܔͭ৷ࣖΥЪd͂ிɓࡈ̙ᓒ࢝˲ᜳݺٙᔼ ᐕ؂ਕ̨̻fҢࡁዹतٙGOLD™ږ೐੃৅ሙ ೻ʿGOLD™-ENږ೐ᚐɻ੃৅ሙ೻ၳೊɽᝄ ਜdЇʦʊଢ଼ࠇމڐɷΤʕ਷ʫήᔼ͛ձᚐ ɻ౤Զ੃৅fҢࡁၾ΢ήਜʿή˙ִ݁ΥЪ කணٙൢהၣഖ͟45ࡈତʊܔϓٙPPP̋ɪ ̤̮གྷ40ࡈࠇྌጳܔٙPPPଡ଼ϓfኋ၍Όଢ຾ ᏶ᐑྤʔ׼ࣦdШҢࡁ͵ೌ৾ɨᓒੵӉͽd ԨʊϓމɽᝄਜՉʕɓࡈ௰ɽژൢၣഖfҢ ࡁ׵͊Ըਗ਼௅໇һεGOLD™ږ೐੃৅ሙ೻ ʿGOLD™-ENږ೐ᚐɻ੃৅ሙ೻ٙա৅ᔼ͛ ʿᚐɻ׵ତϞʿอணٙPPPൢהאൈᏝᔼᐕ̻ ̨d˸౤৷ɽᝄਜٙᔼᐕ؂ਕ˥̻ʿᓒɽ̹ ఙf ܵᚃϓ̌ٙᗫᒟί׵௴อdतй݊ίʕ਷ʫ ήவছᕼɽձʔᓙᄣڗ̹ٙఙf͉ණྠԐί ۃضdˏჯ̹ఙࠬΣf׵2020ϋ8˜dҢࡁ͍ όක࢝ʝᑌၣᔼ৫ุਕfЪމਬɓᐏ཯೯ʝ ᑌၣᔼ৫೐๫ٙ࠰ಥᔼᐕڭ਄̨̻dҢࡁਗ਼ ீཀ࿩ɨٙԄᔼၣഖ˸ʿၾอආձତϞਖ਼߅ ᔼ͛ණྠ೯࢝ٙ኷ଫྫМᗫڷdᘱᚃމઃ٫ ձʫή֢͏౤ԶΥجٙჃ೻ᔼᐕ؂ਕf

The technique of making use of the right time to introduce the right business decision for the future is the essence of the art of management. This is what we meant by: " ༶ᘪ੯ℭdӔ௷ɷԢ (Devising strategies within a command post that will assure victory a thousand miles away)". Contrary to widespread pessimism in the economic outlook, we have confidence in the growth engine of China especially in the field of healthcare. Our stable cashflow position enabled us to ramp up our expansion plan to open a new headquarter in the central business district of Shenzhen with a total floor space of approximately 11,000 sq. feet to facilitate the administration of GOLDTM and GOLDTM-EN trainings as well as the capturing of potential GBA-based business opportunities.

ၚ๟ࣅ࣌ࣛዚdᘱϾપ͍̈ᆽٙਠุӔഄٙ Ҧ̷d̙ፗ၍ଣᖵஔٙၚ᜖הίd͵у˜༶ᘪ ੯ℭdӔ௷ɷԢ™fତʦٟึ࿁຾᏶ۃ౻Ꮞ ဘేᝈઋၫdҢࡁۍ౲׵ˀՉ༸ϾБd࿁ʕ ਷ٙᄣڗਗɢ̂တڦːd຅ʕˈ˸ᔼᐕჯਹ މ್fҢࡁᖢ֛ٙତږݴًرᜫҢࡁ̙˸̋ ɽᓒੵࠇྌdίଉέٙਠุʕːਜਹணͭᐼ ᅽࠦ٤ගߒމ11,000 ̻˙ъٙอᐼ௅d͜׵ GOLD™ږ೐੃৅ሙ೻ʿGOLD™-ENږ೐ᚐ ɻ੃৅ሙ೻ٙ၍ଣʈЪd˸ʿࣉ࣍ɽᝄਜٙ ᆑίਠዚf

Our unwavering commitment in GBA will also bring synergy to the heart of our Hong Kong business. Spurred on by our service excellence and increasing brand presence in the GBA, once traveling resumes, Mainland travelers will be gravitated towards our existing primary care network, growing specialist services scope and differentiated healthcare solutions in Hong Kong. We are poised to strengthen our self-reinforcing business flywheel by capturing the flows of talent and business opportunities between the two regions.

Ңࡁ࿁ɽᝄਜٙ਺֛וፕɰਗ਼މ࠰ಥࣨːุ ਕ੭Ը՘ΝࣖूfίҢࡁ׵ɽᝄਜٙՙ൳؂ ਕձᑊᚑ˚ඤٙۜ೐ࣖूપਗɨdɓ͇ʫή ၾ࠰ಥܨూ͍੬ֻ༷ࣚԸdʫήࣚ܄ਗ਼މҢ ࡁତϞٙਿᄴᔼᐕၣഖeʔᓙᄣڗٙਖ਼߅؂ ਕᇍఖձ࠰ಥჯ΋Ν኎ٙᔼᐕ༆Ӕ˙ࣩהі ˏfҢࡁਗ਼ஷཀҪ౥Շήʘගٙɛʑʿਠዚ ݴਗd̋੶ණྠ͉ԒʔᓙІҢᄣ੶ุٙਕ᜗ ӻf

Our goal is to build on our existing business practice that exemplifies our corporate vision, which is "to give everyone access to trusted and affordable care so that everyone can freely pursue their dreams without worrying about their health." Such vision and our development trajectory are intertwined. We firmly believe that we can maximize our growth potential while continuing to be a pioneer of change in the healthcare space.

Ңࡁٙͦᅺ݊ίତϞุਕྼስɪΎટΎᄒd ᜗ତҢࡁٙΆุᗴ౻d˜ᜫהϞɛᐏ੻̙ڦ΂ ʿ̙ࠋዄٙ؂ਕd੽Ͼίʔ͜ዄː਄ੰٙϽ ᅇɨd৛ӋІʉٙྫྷซ™fவࡈᗴ౻ၾҢࡁٙ ೯࢝༩ࢰʝ޴໾ԑʿࠠᛌfҢࡁ਺ڦҢࡁঐ ੄း࢝ᄣڗᆑɢdԨᘱᚃίᔼᐕڭ਄ჯਹዄ ຅ᜊࠧٙ΋ᚨf

OUR BUSINESS

UMP's business scope consists of the following business lines:

我們的業務

ᑌΥᔼਕุٙਕᇍᖚܼ̍˸ɨุਕᇞj

1.

Hong Kong & Macau Corporate Healthcare Solution Services

UMP provides corporate healthcare solutions through the design and administration of tailored healthcare benefits plans for its Contract Customers. The extension of Third Party Administration service to our insurance company clients since last year enriched UMP's corporate healthcare solutions scope. UMP aims to provide convenient, reliable, coordinated, comprehensive and affordable healthcare services through our well-established and multi-specialties UMP Network. As at 31 December 2020, the UMP Network comprises more than 800 points of services located across Hong Kong and Macau.

The Group's Contract Customers comprise (i) insurance companies, who enter into contracts with the Group for healthcare services for their policyholders or employees of their policyholders and (ii) corporations, who enter into contracts with the Group for healthcare services for their employees and/or their dependants. When designing healthcare benefits plans, the Group collaborates closely with the Contract Customers and designs and refines corporate healthcare benefits plans, with each plan tailored to each customer's needs based on factors such as industry or occupational health-related concerns, scope of healthcare benefits desired, employee demographic as well as their budget.

1.

香港及澳門企業醫療保健解決方案 服務 ᑌΥᔼਕஷཀணࠇʿ၍ଣ০࿁ՉΥߒ܄ ˒ܓԒ֛Ⴁٙᔼᐕڭ਄၅лࠇྌd౤Զ Άุᔼᐕڭ਄༆Ӕ˙ࣩfІ̘ϋৎd͉ ණྠਗ਼ୋɧ˙၍ଣ؂ਕן࢝ЇҢࡁڭᎈ ʮ̡܄˒dᓒɽᑌΥᔼਕٙΆุᔼᐕڭ ਄༆Ӕ˙ࣩᇍఖfᑌΥᔼਕϙίஷཀҁ ഛʿεࡈʔΝਖ਼߅ٙUMPၣഖd౤Զک ઠe̙ቦe՘ሜeΌࠦʿྼ౉ٙᔼᐕڭ ਄؂ਕf׵ 2020ϋ12˜31˚dUMPၣ ഖܼ̍൴ཀ800ࡈЗ׵࠰ಥʿዦژٙ؂ ਕᓃf ͉ණྠٙΥߒ܄˒ܼ̍(i)ڭᎈʮ̡dމ ־ഃڭఊܵϞɛאڭఊܵϞɛٙ྇ࡰఱ ᔼᐕڭ਄؂ਕၾ͉ණྠࠈͭΥߒiʿ(ii) Άุdމ־ഃ྇ࡰʿŊא־ഃʘաቮɛ ఱᔼᐕڭ਄؂ਕၾ͉ණྠࠈͭΥߒfί ணࠇᔼᐕڭ਄၅лࠇྌࣛd͉ණྠၾΥ ߒ܄˒੗ʲΥЪdணࠇʿᎴʷΆุᔼᐕ ڭ਄၅лࠇྌd࣬ኽБุאϞᗫٙᔖุ ਄ੰਪᕚeהცᔼᐕ၅лٙᇍఖe྇ࡰ तᅄʿՉཫၑක˕ഃΪ९d০࿁ӊɓ܄ ˒ٙცӋ౤ԶܓԒ֛Ⴁٙࠇྌf

• 2. Hong Kong & Macau Clinical Healthcare Services

  UMP provides medical, dental and auxiliary services to Self-paid Patients. For medical services, UMP provides (i) general practice services, which serves as the first point of contact for the patients and (ii) specialist services covering more than 16 different specialties. For dental services, UMP provides both primary dental care and secondary dental care such as dental implants. For auxiliary services, UMP provides services such as medical imaging and laboratory services, physiotherapy and vision care.

  • 2. 香港及澳門臨床醫療保健服務

    ᑌΥᔼਕΣІ൬ઃ٫౤Զᔼᐕe˫߅ʿ

    Ⴞп؂ਕfᔼᐕ؂ਕ˙ࠦdᑌΥᔼਕ౤

    Զ(i)Ό߅ᔼᐕ؂ਕdމઃ٫ٙ࠯ࡈટᙃ

    ᓃiʿ(ii)ਖ਼߅؂ਕdᔧႊ൴ཀ16ࡈʔΝ

    ਖ਼߅f˫߅؂ਕ˙ࠦdᑌΥᔼਕ౤Զਿ

    ͉˫߅ᚐଣʿୋɚᄴ˫߅ᚐଣ€Էνಔ

    ˫fႾп؂ਕ˙ࠦdᑌΥᔼਕ౤Զᔼ

    ኪᅂ྅ʿʷ᜕؂ਕeيଣطᐕ˸ʿ଻߅

    ᚐଣഃ؂ਕf

• 3. PRC Healthcare Business

  Our PRC Healthcare Business currently consists of (i) health check-up business; (ii) corporate healthcare solutions business for contract customers; (iii) selected outpatient services such as family medicine within the clinics we own and operate; (iv) provision of online tele-consultation service and (v) provision of professional training to doctors and nurses under our GOLD™ training programme. Our current focus is on the development of our PRC Healthcare Business in Beijing, Shanghai, Guangzhou, Shenzhen and other GBA , through both building a sizeable offline PPP network and an online presence through our tele-consultation platform.

BUSINESS LINES ANALYSIS

Hong Kong & Macau Corporate Healthcare Solution Services

Revenue for this business line has decreased 5.9% from HK$129.9 million to HK$122.3 million (before inter-segment elimination) due to a general decrease in patient visits.

• 3. 中國保健業務

  Ңࡁٙʕ਷ڭ਄ุਕͦۃܼ̍(i)᜗Ꮸุ

  ਕi(ii)؂ਕΥߒ܄˒ٙΆุᔼᐕڭ਄༆

  Ӕ˙ุࣩਕi(iii)ίҢࡁኹϞʿᐄ༶ٙൢ

  הʫ౤Զ፯֛ژൢ؂ਕ€ν࢕ࢬᔼኪi

  (iv) ౤ԶίᇞჃ೻ᔼᐕ؂ਕiʿ (v) ࣬ኽ

  ҢࡁٙGOLD™ږ೐੃৅ሙ೻Σᔼ͛ʿ

  ᚐɻ౤Զਖ਼ุ੃৅fҢࡁͦۃٙࠠᓃ݊

  Νࣛீཀ͂ிՈ஝ᅼٙྼ᜗PPPၣഖ˸

  ʿீཀҢࡁٙჃ೻ᔼᐕ؂ਕ̨̻౤Զٙ

  ၣɪ؂ਕdί̏ԯeɪऎeᄿψeଉέ

  ʿɽᝄਜʫٙՉ˼ήਜ೯࢝ʕ਷ڭ਄ุ

  ਕf

業務線分析 香港及澳門企業醫療保健解決方案服務

ԸІϤุਕᇞٙϗɝ͟ 129.9 ϵຬಥʩಯˇ 5.9%Ї122.3 ϵຬಥʩ€ʱ௅ගתቖۃdɗ ͟׵ఱൢɛϣ዆᜗ɨࠥf

Hong Kong & Macau Clinical Healthcare Services

Revenue for this business line has increased approximately 5.7% from HK$201.6 million to HK$213.1 million (before inter-segment elimination) due to a general increase in number of health check-ups and average spending per visit.

香港及澳門臨床醫療保健服務

ԸІϤุਕᇞٙϗɝ͟201.6ϵຬಥʩᄣ̋ߒ 5.7%Ї213.1 ϵຬಥʩ€ʱ௅ගתቖۃdɗ ͟׵౤Զٙ᜗Ꮸϣᅰʿ̻ѩൢ൬዆᜗ᄣ̋f

Our business lines in Hong Kong and Macau are mature and continue to generate profit and operating cash flows for investment in new growth areas.

Ңࡁί࠰ಥձዦژุٙਕᇞʊ຾೯࢝ϓᆞd Ԩܵᚃପ͛лᆗձ຾ᐄତږݴϾ̙͜׵ҳ༟ อٙᄣڗჯਹf

PRC Healthcare Business

Revenue for this business line has decreased approximately 26.3% from HK$27.7 million to HK$20.4 million (before inter-segment elimination) primarily due to the decrease in the number of health check-ups which was a direct result of COVID-19 impacted travel restrictions. We continue to invest in people and technology for the rapid development of GOLD™ medical professional training and the virtual care businesses in Mainland China and mainly the GBA.

Mainland China presents significant growth opportunities and is a point of focus for us as we continue to innovate and develop new business lines.

中國保健業務

ԸІϤุਕᇞٙϗɝ͟27.7ϵຬಥʩಯˇߒ 26.3%Ї20.4 ϵຬಥʩ€ʱ௅ගתቖۃdɗ ˴ࠅ͟׵ΪᏐอۨڿًषݭϾྼ݄༷ٙࣚࠢ Փd੽Ͼ˿౤Զٙ᜗ᏨϣᅰಯˇfҢࡁᘱᚃ ίʕ਷ʫή€˴ɢ݊ίɽᝄਜҳ༟׵ɛʑʿ ߅Ҧ˸પਗGOLDTMږ೐ᔼᐕਖ਼ุ੃৅ʿჃ೻ ᔼᐕุਕٙԘ஺೯࢝fʕ਷ɽ௔ᘾᔛ̙ᝈٙ ᄣڗዚ༾dɰ݊Ңࡁᘱᚃ௴อձ೯࢝อุਕ ᇞٙࠠᓃהίf

The following table sets out the revenue for our business lines for the six months ended 31 December 2020 and the corresponding period for comparison:

ɨڌ༱ΐҢࡁ࿚Ї2020ϋ12˜31˚˟ʬࡈ˜ ˸ʿ޴Ꮠಂගุٙਕᇞϗɝ˸Զˢ༰j

Revenue by business lines

按業務線劃分收入

Six months ended 31 December 截至12月31日止六個月

Increase/ (decrease)

FINANCIAL REVIEWS

1HFY2021 compared to 1HFY2020

Revenue

During 1HFY2021, we primarily generated revenue from (i) the provision of corporate healthcare solutions to Contract Customers in Hong Kong and Macau; (ii) the provision of clinical healthcare services in Hong Kong and Macau and (iii) the provision of healthcare services in the PRC.

財務回顧 2021財政年度上半年與2020財政年度上 半年比較 收入 ׵2021ৌ݁ϋܓɪ̒ϋdҢࡁٙϗɝ˴ࠅପ ͛І(i)׵࠰ಥʿዦژΣΥߒ܄˒౤ԶΆุᔼᐕ ڭ਄༆Ӕ˙ࣩi(ii)׵࠰ಥʿዦژ౤Զᑗґᔼ ᐕڭ਄؂ਕʿ(iii)׵ʕ਷౤Զᔼᐕڭ਄؂ਕf

Total consolidated revenue decreased by 1.5% from HK$306.8 million in 1HFY2020 to HK$302.1 million in 1HFY2021, primarily due to a decrease in revenue from HK$27.7 million to HK$20.4 million from the PRC Healthcare Business.

ᐼၝΥϗɝ͟2020ৌ݁ϋܓɪ̒ϋ306.8ϵຬ ಥʩಯˇ 1.5%Ї2021 ৌ݁ϋܓɪ̒ϋ 302.1

ϵຬಥʩdɗ˴ࠅ͟׵ԸІʕ਷ڭ਄ุਕٙ ϗɝ͟27.7ϵຬಥʩಯˇЇ20.4ϵຬಥʩf

Provision of corporate healthcare solution services to Contract Customers in Hong Kong and Macau

Revenue from the provision of corporate healthcare solution services to Contract Customers in Hong Kong and Macau decreased 5.8% from HK$129.1 million in 1HFY2020 to HK$121.6 million in 1HFY2021.

׵࠰ಥʿዦژΣΥߒ܄˒౤ԶΆุᔼᐕڭ਄ ༆Ӕ˙ࣩ؂ਕ

ԸІΣ࠰ಥʿዦژٙΥߒ܄˒౤ԶΆุᔼᐕ ڭ਄༆Ӕ˙ࣩ؂ਕٙϗɝ͟2020ৌ݁ϋܓɪ

̒ϋ 129.1 ϵຬಥʩಯˇ 5.8%Ї2021 ৌ݁ϋ ܓɪ̒ϋ121.6ϵຬಥʩf

• • Medical. Revenue generated from the provision of Medical Services to Contract Customers decreased by 5.9% from HK$116.7 million for 1HFY2020 to HK$109.8 million for 1HFY2021, primarily due to a decrease in the number of visits from patients seeking Medical Services.

  • • 醫療。ΣΥߒ܄˒౤Զᔼᐕ؂ਕٙϗ ɝ͟ 2020 ৌ݁ϋܓɪ̒ϋ 116.7 ϵຬ ಥʩಯˇ5.9%Ї2021ৌ݁ϋܓɪ̒ϋ 109.8ϵຬಥʩdɗ˴ࠅ͟׵రӋᔼᐕ ؂ਕٙઃ٫ఱൢϣᅰಯˇf

• • Dental. Revenue generated from the provision of Dental Services to Contract Customers decreased by 4.8% from HK$12.4 million for 1HFY2020 to HK$11.8 million for 1HFY2021, primarily due to a decrease in the number of visits from the patients seeking Dental Services.

• • 牙科。ΣΥߒ܄˒౤Զ˫߅؂ਕٙϗ ɝ͟2020ৌ݁ϋܓɪ̒ϋ12.4ϵຬಥ ʩಯˇ 4.8%Ї2021 ৌ݁ϋܓɪ̒ϋ 11.8 ϵຬಥʩdɗ˴ࠅ͟׵రӋ˫߅ ؂ਕٙઃ٫ఱൢϣᅰಯˇf

Provision of clinical healthcare services in Hong Kong and Macau

• • Medical. Revenue generated from the provision of Medical Services to Self-paid Patients increased by 9.2% from HK$121.5 million for 1HFY2020 to HK$132.7 million for 1HFY2021, primarily due to an increase in the average spending per visit.

  ׵࠰ಥʿዦژ౤Զᑗґᔼᐕڭ਄؂ਕ

  • • 醫療。ΣІ൬ઃ٫౤Զᔼᐕ؂ਕٙϗ ɝ͟ 2020 ৌ݁ϋܓɪ̒ϋ 121.5 ϵຬ ಥʩᄣ̋9.2%Ї2021ৌ݁ϋܓɪ̒ϋ 132.7ϵຬಥʩdɗ˴ࠅ͟׵ϣѩൢ൬ ᄣ̋f

• • Dental. Revenue generated from the provision of Dental Services to Self-paid Patients decreased by approximately 3.5% from HK$28.4 million for 1HFY2020 to HK$27.4 million for 1HFY2021 due to the decrease in number of self-paid patient visits.

• • 牙科。ΣІ൬ઃ٫౤Զ˫߅؂ਕٙϗ ɝ͟2020ৌ݁ϋܓɪ̒ϋ28.4ϵຬಥ ʩಯˇߒ3.5%Ї2021ৌ݁ϋܓɪ̒ϋ 27.4 ϵຬಥʩdɗ˴ࠅ͟׵І൬ઃ٫ ఱൢϣᅰಯˇf

PRC Healthcare Business

Revenue generated from the PRC Healthcare Business decreased from HK$27.7 million in 1HFY2020 to HK$20.4 million in 1HFY2021, primarily due to a decrease in the number of health check-ups for PRC residents traveling abroad for study or work and health check-ups for corporate employees and insurance scheme members, which was significantly impacted by COVID-19 related travel restrictions.

ʕ਷ڭ਄ุਕ

ԸІʕ਷ڭ਄ุਕٙϗɝ͟2020ৌ݁ϋܓɪ ̒ϋ27.7ϵຬಥʩಯЇ2021ৌ݁ϋܓɪ̒ϋ 20.4 ϵຬಥʩdɗ˴ࠅ͟׵މՑऎ̮वኪא ʈЪٙʕ਷֢͏౤Զٙ᜗Ꮸϣᅰ˸ʿމΆุ ྇ࡰʿڭᎈࠇྌϓࡰ౤Զٙ᜗ᏨϣᅰաՑอ ۨڿًषݭ޴ᗫ̈ɝྤࠢՓٙᜑഹᅂᚤϾಯ ˇf

Other Income and Gains

Other income and gains primarily comprise administrative support fees (including fees derived from providing administrative support to Affiliated Doctors, Affiliated Dentists and Affiliated Auxiliary Services Providers), bank interest income, interest income from financial assets at amortised cost, dividend income from investments at fair value through other comprehensive income and investments at fair value through profit or loss, gain on disposal of subsidiaries and fixed assets, and other income.

其他收入及收益

Չ˼ϗɝʿϗू˴ࠅܼ̍Б݁˕౪൬͜€̍ ܼΣᑌ᙮ᔼ͛eᑌ᙮˫ᔼʿᑌ᙮Ⴞп؂ਕ౤ Զ٫౤ԶБ݁˕౪הପ͛ٙ൬͜eვБлࢹ ϗɝeܲᛅቖϓ͉ࠇඎٙږፄ༟ପٙлࢹϗ ɝeܲʮʪᄆ࠽ࠇɝՉ˼Όࠦϗɝٙҳ༟˸ ʿܲʮʪᄆ࠽ࠇɝฦूٙҳ༟ʘٰࢹϗɝe ̈ਯڝ᙮ʮ̡ʿո֛༟ପʘϗूd˸ʿՉ˼ ϗɝf

Other income and gains decreased by 65.1% from HK$10.9 million in 1HFY2020 to HK$3.8 million in 1HFY2021. The decrease was primarily due to decrease in dividend income received from an investment at fair value through other comprehensive income.

Չ˼ϗɝʿϗू͟2020ৌ݁ϋܓɪ̒ϋ10.9 ϵຬಥʩಯˇ65.1%Ї2021ৌ݁ϋܓɪ̒ϋ 3.8ϵຬಥʩfՉಯˇ˴ࠅ͟׵੽ɓධܲʮʪ ᄆ࠽ࠇɝՉ˼Όࠦϗɝٙҳ༟ϗ՟ٰٙࢹϗ ɝಯˇהߧf

Professional Services Expenses

Professional services expenses primarily comprise fees paid to

Doctors, Dentists and Auxiliary Services Providers for Medical Services, Dental Services and Auxiliary Services rendered within the UMP Network, as well as fees paid to third party laboratories and testing centres for services rendered to the Group.

專業服務費用 ਖ਼ุ؂ਕ൬͜˴ࠅܼ̍ఱᔼ͛e˫ᔼʿႾп ؂ਕ౤Զ٫׵UMPၣഖʫ౤Զٙᔼᐕ؂ਕe ˫߅؂ਕʿႾп؂ਕΣՉ˕˹ٙ൬͜d˸ʿ ఱୋɧ˙ʷ᜕ʿᏨ಻ʕːΣ͉ණྠ౤Զٙ؂ ਕϾ˕˹ٙ൬͜f

Professional services expenses decreased by 9.3% from HK$122.2 million for 1HFY2020 to HK$110.8 million for 1HFY2021, primarily due to a decrease in the cost of services rendered by doctors, dentists and other professionals.

ਖ਼ุ؂ਕ൬͜͟ 2020 ৌ݁ϋܓɪ̒ϋ 122.2 ϵຬಥʩಯˇ 9.3%Ї2021 ৌ݁ϋܓɪ̒ϋ 110.8ϵຬಥʩd˴ࠅ͟׵ᔼ͛e˫ᔼʿՉ˼ ਖ਼ุɛɻ౤Զ؂ਕٙϓ͉ಯˇf

Property Rental and Related Expenses

Property rental and related expenses decreased by 34.9% from HK$6.3 million for 1HFY2020 to HK$4.1 million for 1HFY2021, primarily due to the rental concessions granted by landlords of various premises.

物業租金及相關開支 يุॡږʿ޴ᗫක˕͟2020ৌ݁ϋܓɪ̒ϋ 6.3ϵຬಥʩಯˇ34.9%Ї2021ৌ݁ϋܓɪ̒ ϋ4.1ϵຬಥʩd˴ࠅ͟׵ʔΝஈהุٙ˴ഗ ʚॡږಯеf

Depreciation and Amortisation

Depreciation and amortisation, which comprises of depreciation of the right-of-use assets and depreciation and amortisation of other non-current assets, increased by 14.1% from HK$35.4 million in 1HFY2020 to HK$40.4 million for 1HFY2021, primarily due to the increase of depreciation because of decoration and acquisitions of plant and equipment.

折舊及攤銷 ұᔚʿᛅቖ€ܼ̍Դ͜ᛆ༟ପұᔚ˸ʿՉ˼ڢ ݴਗ༟ପʘұᔚʿᛅቖ͟ 2020ৌ݁ϋܓɪ ̒ϋٙ 35.4 ϵຬಥʩᄣ̋ 14.1%Ї2021 ৌ݁ ϋܓɪ̒ϋٙ40.4 ϵຬಥʩd˴ࠅ݊͟׵ༀ ࡌʈ೻˸ʿᒅໄዚኜʿண௪˿ұᔚᄣ̋f

Other Expenses, net

Other expenses, net primarily comprise provision of impairment loss, warrants expenses and general overhead expenses such as utilities, operation and other administrative expenses such as audit fees, legal fees, repair and maintenance expenses incurred with respect to the Group's offices and medical equipment, printing expenses and bank charges.

其他開支淨額

Չ˼ක˕ଋᕘ˴ࠅܼ̍ಯ࠽ᑦฦᅡ௪eႩٰ ᛆᗇක˕˸ʿ˚੬කቖdԷν˥ཥe຾ᐄʿ Չ˼Б݁ක˕€Էνᄲࣨ൬͜eجܛ൬͜eၾ ͉ණྠ፬ʮ܃ʿᔼᐕண௪޴ᗫٙၪࡌʿڭቮ ක˕eΙՏ൬ʿვБϗ൬f

Other expenses, net, increased by 403.1% from approximately HK$6.4 million in 1HFY2020 to HK$32.2 million in 1HFY2021, primarily due to an impairment of other assets of HK$4.1 million, an impairment of deposit of HK$4.1 million in 1HFY2021, and a reversal of the non-cash equity-settled share-based payment expense of approximately HK$15.2 million was recorded in 1HFY2020 since the associated terms and conditions for the Second and Third Vesting Milestones had not been met before its expiration on 14 November 2019, which did not recur in 1HFY2021.

Չ˼ක˕ଋᕘ͟2020ৌ݁ϋܓɪ̒ϋٙߒ6.4 ϵຬಥʩᄣ̋403.1%Ї2021ৌ݁ϋܓɪ̒ϋ ٙ32.2 ϵຬಥʩd˴ࠅ͟׵ 2021ৌ݁ϋܓɪ ̒ϋʫϞՉ˼༟ପʘಯ࠽މ4.1ϵຬʩdܲږ ʘಯ࠽މ4.1ϵຬʩdʿ2020ৌ݁ϋܓɪ̒ϋ ʫᅡΫڢତږ˸ᛆूഐၑٰٙ΅˕˹ක˕ߒ 15.2 ϵຬಥʩdࡡΪމୋɚධʿୋɧධᓥ᙮ Ԣ೻຦ʘ޴ᗫૢಛʿૢ΁ԨೌίՉ׵2019ϋ 11˜14˚֣တۃ༺ϓdϾϤධͦ׵2021ৌ݁ ϋܓɪ̒ϋԨೌΎϣ̈ତf

Summary of operational data for 1HFY2021 with comparative figures for 1HFY2020

Revenue by operating segment

2021財政年度上半年的經營數據與2020財政 年度上半年比較數據概要 ܲ຾ᐄʱ௅ྌʱϗɝ

Six months ended 31 December 截至12月31日止六個月

Increase/ (decrease)

Number of visits by operating segment

ܲ຾ᐄʱ௅ྌʱఱൢϣᅰ

Six months ended 31 December 截至12月31日止六個月

Increase/ (decrease)

KEY FINANCIAL POSITION ITEMS

Right-of-use assets

Under HKFRS 16, right-of-use assets are recognised at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. The recognised right-of-use assets are depreciated on a straight-line basis over the shorter of the estimated useful life and the lease term.

As at 31 December 2020, the Group's right-of-use assets amounted to HK$75.5 million (30 June 2020: HK$82.2 million).

׵2020ϋ12˜31˚d͉ණྠٙԴ͜ᛆ༟ପމ 75.5 ϵຬಥʩ€ 2020ϋ6˜30˚j82.2ϵຬಥ ʩf

Financial Assets at Amortised Cost

Financial assets at amortised cost primarily represent the marketable corporate bonds issued by listed corporations with fixed interest rates from 4.25% to 8.50% per annum. The marketable debt securities which will mature within one year and more than one year are classified as current assets and non-current assets, respectively. The Group receives related interest payments semi-annually and annually.

按攤銷成本計量的金融資產 ܲᛅቖϓ͉ࠇඎٙږፄ༟ପ˴ࠅܸɪ̹ʮ̡ ೯Бٙቇቖʮ̡වՎdܲո֛ϋлଟ 4.25% Ї8.50% ࠇࢹf׵ɓϋʫʿɓϋܝՑಂٙቇ ቖවਕᗇՎʱйʱᗳމݴਗ༟ପʿڢݴਗ༟ ପf͉ණྠӊ̒ϋʿӊϋϗ՟޴ᗫлࢹ˹ಛf

As at 31 December 2020 and 30 June 2020, the Group's financial assets at amortised cost amounted to HK$50.0 million (of which HK$17.1 million is classified as current assets and HK$32.9 million is classified as non-current assets) and HK$55.8 million (of which HK$35.6 million is classified as current assets and HK$20.2 million is classified as non-current assets), respectively.

׵2020ϋ12˜31 ˚ʿ 2020ϋ6˜30˚d͉ ණ ྠܲᛅቖϓ͉ࠇඎٙږፄ༟ପʱйމ50.0ϵ ຬಥʩ€Չʕ 17.1 ϵຬಥʩʱᗳމݴਗ༟ପ Ͼ32.9ϵຬಥʩʱᗳމڢݴਗ༟ପʿ55.8ϵ ຬಥʩ€Չʕ35.6ϵຬಥʩʱᗳމݴਗ༟ପϾ 20.2ϵຬಥʩʱᗳމڢݴਗ༟ପf

Lease liabilities

Under HKFRS 16, lease liabilities are recognised at the commencement date of the lease at the present value of lease payments to be made over the lease term. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made.

租賃負債 ࣬ኽ࠰ಥৌਕజѓ๟ۆୋ16໮dॡ༣ࠋවί ॡ༣ක֐˚ಂ˸ίॡ༣ಂʫਗ਼Ъ̈ٙॡ༣˹ ಛٙତ࠽ᆽႩfίක֐˚ಂʘܝdॡ༣ࠋව ٙږᕘʚ˸ɪሜ˸ˀ݈лࢹٙᄣ̋dԨఱʊ Ъ̈ٙॡ༣˹ಛϾಯˇf

As at 31 December 2020 and 30 June 2020, the carrying amount of lease liabilities amounted to HK$83.0 million (of which HK$51.4 million is classified as current liabilities and HK$31.6 million is classified as non-current liabilities) and HK$86.5 million (of which HK$43.4 million is classified as current liabilities and HK$43.1 million is classified as non-current liabilities).

׵2020ϋ12˜31 ˚ʿ 2020ϋ6˜30˚dॡ ༣ ࠋවٙሪࠦ࠽ʱйމ83.0ϵຬಥʩ€Չʕ51.4 ϵຬಥʩʱᗳމݴਗࠋවϾ31.6ϵຬಥʩʱ ᗳމڢݴਗࠋවʿ 86.5 ϵຬಥʩ€Չʕ 43.4 ϵຬಥʩʱᗳމݴਗࠋවϾ43.1ϵຬಥʩʱ ᗳމڢݴਗࠋවf

LIQUIDITY AND FINANCIAL RESOURCES

The Group has historically funded its operations primarily by cash generated from operating activities. Upon the listing of the shares of the Company on the Hong Kong Stock Exchange, the Group intended to satisfy its liquidity requirements using a combination of cash generated from operating activities and net proceeds from the Global Offering. The Group may also seek to borrow to satisfy liquidity requirements. As of 31 December 2020, the Group had a cash and cash equivalents of HK$235.0 million.

流動資金及財務資源

͉ණྠཀֻ˴ࠅீཀ຾ᐄݺਗה੻ତږ˕ܵ Չุਕ຾ᐄf͉ʮٰ̡΅׵࠰ಥᑌʹהɪ̹ ܝd͉ණྠᏝਗ͜຾ᐄݺਗה੻ତږʿΌଢ ೯ਯה੻ಛධଋᕘԸတԑՉݴਗ༟ږცӋf ͉ණྠ͵̙ঐరӋ࠾ಛԸတԑݴਗ༟ږც Ӌf࿚Ї2020ϋ12˜31˚d͉ණྠܵϞٙତ ږʿତږഃᄆيމ235.0ϵຬಥʩf

As of the date of this report, the Group did not have any bank borrowings or outstanding bank loans and did not enter into any bank loan facilities.

࿚Ї͉జѓ˚ಂd͉ණྠԨೌ΂ОვБ࠾ಛ א͊ᎵᒔვБ൲ಛd͵ೌࠈͭ΂ОვБ൲ಛ ፄ༟f

PLEDGE OF ASSETS

As at 31 December 2020, the Group has pledged certain deposits with an aggregate carrying amount of HK$1.0 million (30 June 2020: HK$1.4 million) in connection with a surety bond issued by a bank in favour of an independent third party for potential damages of dental equipment and potential disruption of Medical Services, and a bank guarantee issued by a bank in favour of a landlord for leasing of a medical centre of the Group.

資產抵押

׵2020ϋ12˜31˚d͉ණྠתץሪࠦ࠽Υ΍ 1.0ϵຬಥʩ€2020ϋ6˜30˚j1.4ϵຬಥʩ ٙ߰ʍπಛdɗϞᗫ͟ɓගვБΣɓΤዹͭ ୋɧ˙ఱᆑί˫߅ண௪ฦᕸʿᔼᐕ؂ਕٙᆑ ίʍᓔ೯̈ٙᄵߒڭᗇ˸ʿ͟ɓගვБఱ͉ ණྠॡ༣ɓගᔼਕʕːΣุ˴Ъ̈ٙვБዄ ڭf

EMPLOYEE AND REMUNERATION POLICY

As at 31 December 2020, the Group had a total of 451 (30 June 2020: 452) full-time employees. For 1HFY2021, the staff cost (including Directors' remuneration in the form of salaries and other benefits) was approximately HK$60.0 million (1HFY2020: HK$72.6 million).

The Group ensures that the pay levels of its employees are competitive and employees are rewarded on a performance related basis, together with reference to the profitability of the Group, prevailing remuneration benchmarks in the industry, and market conditions within the general framework of the Group's remuneration system.

僱員及薪酬政策

׵ 2020 ϋ 12 ˜ 31 ˚d͉ණྠ΍Ϟ 451Τ €2020ϋ6˜30˚j452ΤΌᔖ྇ࡰf׵2021 ৌ݁ϋܓɪ̒ϋdࡰʈϓ͉€ܼ̍˸ᑚږʿ Չ˼၅лҖόٙ໨ԫᑚཇߒމ60.0ϵຬಥʩ €2020ৌ݁ϋܓɪ̒ϋj72.6 ϵຬಥʩf ͉ණྠᆽڭՉ྇ࡰٙᑚږ˥̻Ոᘩنɢd྇ ࡰܲʈЪڌତਿ๟ᐏ੻ᆤᎸd˲຾ਞϽ͉ණ ྠޮлঐɢeБุʫତБٙᑚཇਿ๟˸ʿ͉ ණྠᑚཇ᜗ӻ዆᜗࣪ݖʫ̹ٙఙًرf

In addition, the Company also adopted the Pre-IPO Share Option Scheme and the Post-IPO Share Option Scheme, where eligible employees and consultants are entitled to subscribe for the Shares for their contribution to the Group. As at 31 December 2020, 27,008,000 options remained outstanding under the Pre-IPO Share Option Scheme and none of the share options under the Pre-IPO Share Option Scheme have been exercised during 1HFY2021.

As at 31 December 2020, 19,270,000 options granted under the Post-IPO Share Option Scheme and none of the share options under the Post-IPO Share Option Scheme have been exercised during 1HFY2021.

The Company has also adopted the Share Award Scheme to provide an incentive and reward to selected participants for their contribution to the Group. Certain Shares have been purchased and no Shares have been granted under the Share Award Scheme during 1HFY2021.

Ϥ̮d͉ʮ̡͵મॶ࠯ϣʮක೯ਯۃᒅٰ ᛆࠇྌʿ࠯ϣʮක೯ਯܝᒅٰᛆࠇྌdϾ Υ༟ࣸ྇ࡰʿᚥਪΪ־ഃ࿁͉ණྠЪ্̈ ᘠϾϞᛆႩᒅٰ΅f׵ 2020ϋ12˜31˚d 27,008,000΅ᒅٰᛆ֠͊࣬ኽ࠯ϣʮක೯ਯ ۃᒅٰᛆࠇྌБԴdԨೌᒅٰᛆʊ׵2021ৌ ݁ϋܓɪ̒ϋ࣬ኽ࠯ϣʮක೯ਯۃᒅٰᛆࠇ ྌᐏБԴf׵2020ϋ12˜31˚d࣬ኽ࠯ϣʮ ක೯ਯܝᒅٰᛆࠇྌબ̈ٙ19,270,000΅ᒅ ٰᛆ֠͊ᐏБԴdԨೌᒅٰᛆʊ׵2021ৌ݁ ϋܓɪ̒ϋ࣬ኽ࠯ϣʮක೯ਯܝᒅٰᛆࠇྌ ᐏБԴf ͉ʮ̡͵મॶٰ΅ᆤᎸࠇྌd˸ఱ፯֛ਞၾ ٫࿁͉ණྠЪ্̈ᘠϾΣ־ഃ౤ԶᆤᎸʿΫ జf׵2021ৌ݁ϋܓɪ̒ϋd͉ʮ̡ʊ࣬ኽ ٰ΅ᆤᎸࠇྌᒅɝ߰ʍٰ΅ϾԨೌબٰ̈΅f

The remuneration packages of the Directors are reviewed by the Remuneration Committee and approved by the Board, according to the relevant Director's experience, responsibility, workload and the time devoted to the Group, the Company's operating results and comparable market statistics.

໨ԫᑚཇ˙ࣩ͟ᑚཇ։ࡰึᄲቡԨ͟໨ԫึ ҭࡘdɗ࣬ኽ޴ᗫ໨ԫٙ຾᜕eᔖபeʈЪ ඎʿ׵͉ණྠҳ׳ٙࣛගe͉ʮ̡ٙ຾ᐄุ ᐶʿ̙༟ˢ༰̹ఙᅰኽӔ֛f

INTERIM DIVIDEND

The Board has declared an interim dividend of HK1.00 cent per ordinary share for the six months ended 31 December 2020 (FY2020 interim dividend: HK0.65 cent). The interim dividend will be payable to the shareholders of the Company whose names appear on the register of members of the Company on Thursday, 18 March 2021. It is expected that the interim dividend will be paid on or about Friday, 9 April 2021.

中期股息

໨ԫึʊ܁ݼ࿚Ї2020ϋ12˜31˚˟ʬࡈ˜ ٙʕಂٰࢹӊٰ౷ஷٰ1.00ಥ̀€2020ৌ݁ϋ ܓ ʕ ಂ ٰ ࢹj0.65ಥ̀fʕಂٰࢹਗ਼ݼ˹ʚ ׵2021ϋ3˜18 ˚€݋ಂ̬Τΐ͉ʮٰ̡؇ Τ͉̅ٙʮٰ̡؇fཫಂʕಂٰࢹਗ਼׵2021 ϋ4˜9 ˚€݋ಂʞאۃܝݼ˹f

Corporate Governance Highlights 企業管治摘要

COMPLIANCE WITH THE CORPORATE GOVERNANCE PRACTICES

The Company is committed to maintaining high standards of corporate governance and transparency. The Company confirms that it has complied with the code provisions of the Corporate Governance Code contained in Appendix 14 to the Listing Rules during the six months ended 31 December 2020, save for the deviation from code provision A.2.1 as mentioned below.

遵守企業管治常規

͉ʮ̡ߧɢၪܵ৷˥̻ٙΆุ၍طʿீ׼ ܓf͉ʮ̡ᆽႩdৰɨ˖הࠑ࿁׵Άุ၍ط ςۆୋ A.2.1 ૢʘࠅӋٙ਋ᕎ̮dՉ׵࿚Ї 2020ϋ12˜31˚˟ʬࡈ˜ʊ፭ςɪ̹஝ۆڝ ፽ɤ̬ה༱ʘΆุ၍طςۆٙςۆૢ˖f

According to code provision A.2.1 of the Corporate Governance Code, the roles of the chairman and chief executive should be separate and should not be performed by the same individual.

Dr. Sun Yiu Kwong, the Chairman of the Board, is also the Chief Executive Officer. The Board believes that vesting the roles of both chairman and chief executive in an experienced and qualified person such as Dr. Sun Yiu Kwong provides the Company with strong and consistent leadership while allowing effective and efficient planning and implementation of business decisions and strategies. The Board considers that this structure will not impair the balance of power and authority between the Board and the management of the Group.

࣬ኽΆุ၍طςۆૢ˖ୋA.2.1ૢd˴ࢩၾБ ݁ ᐼ ൒ Ꮠ Ϟ ਜ ʱdԨ ʔ Ꮠ ͟ ɓ ɛ Ν ࣛ ࡒ ΂f ࢑ᘴϪᔼ͛މ໨ԫึ˴ࢩ͵މБ݁ᐼ൒f໨ ԫึႩމd͟࢑ᘴϪᔼ͛வᅵ຾᜕ᔮబٙΥ ༟ࣸɛɻዄ΂˴ࢩࡒБ݁ᐼ൒̙މ͉ʮ̡౤ Զ੶ϾϞɢձᖢ֛ٙჯኬdΝࣛᆽڭ࿁ุਕ ӔഄʿഄଫЪ̈Ϟࣖʿ৷ࣖٙ஝ྌձྼ݄f ໨ԫึႩމdϤഐ࿴ʔึᅂᚤ͉ණྠ໨ԫึ ၾ၍ଣᄴʘගٙᛆɢʿબᛆ̻ፅf

The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

໨ԫึਗ਼ʔࣛᄲቡΆุ၍طݖ࿴ʿ੬஝dԨ ׵ՉႩމቇ຅ࣛЪ̈̀ࠅτરf

THE BOARD

As of the date of this report, the Board comprised nine Directors, including six executive Directors, namely Dr. Sun Yiu Kwong as Chairman and Chief Executive Officer, Ms. Kwok Cheuk Kwan, Jacquen as Managing Director, Mr. Tsang On Yip, Patrick, Dr. Sun Man Kin, Michael, Mr. Lee Kar Chung, Felix and Dr. Lee Pak Cheung, Patrick; and three independent non-executive Directors, namely Mr. Lee Luen Wai, John BBS JP, Dr. Li Kwok Tung, Donald SBS JP and Mr. Yeung Wing Sun, Mike.

董事會

׵͉జѓ˚ಂd໨ԫึ͟ɘЗ໨ԫଡ଼ϓd̍ ܼʬЗੂБ໨ԫdʱйމ࢑ᘴϪᔼ͛€Ъމ˴ ࢩࡒБ݁ᐼ൒eெՙёɾɻ€Ъމ໨ԫᐼ຾ ଣeಀτุ΋͛e࢑˖਺ᔼ͛eҽ࢕ᑋ΋͛ ʿҽݡୂᔼ͛iʿɧЗዹͭڢੂБ໨ԫdʱ йމҽᑌਃ΋͛€ზഓঠ݋௝d˄̻୛ɻeҽ਷ಊ ᔼ͛€ვഓঠ݋௝d˄̻୛ɻʿเ࿲⮹΋͛f

Corporate Governance Highlights 企業管治摘要

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct for dealing in securities of the Company by the Directors.

Having made specific enquiry with all Directors, the Company confirmed that the Directors have complied with the Model Code during the six months ended 31 December 2020.

Relevant employees who are likely to be in possession of inside information of the Group are also subject to compliance with the Code of Conduct for Securities Transactions by Employees on terms that are no less exacting than those set out in the Model Code.

To the best knowledge of the Company, there was no incident of non-compliance of the Code of Conduct for Securities Transactions by Employees during the six months ended 31 December 2020.

進行證券交易的標準守則

͉ʮ̡ʊમॶᅺ๟ςۆЪމ໨ԫ൯ር͉ʮ̡ ᗇՎٙБމςۆf ຾࿁Ό᜗໨ԫЪ̈Ո᜗ݟ༔ܝd͉ʮ̡ᆽႩ ໨ԫ׵࿚Ї2020ϋ12˜31˚˟ʬࡈ˜ʫѩ፭ ςᅺ๟ςۆf ̙ঐ౛౥͉ණྠʫ࿇ऊࢹٙ޴ᗫ྇ࡰ͵඲፭ ς྇ࡰආБᗇՎʹ׸ٙ዁ς๟ۆdՉૢಛʔ Ⴥ׵ᅺ๟ςۆהࠈᅺ๟fఱ͉ʮ̡הٝd࿚ Ї2020ϋ12˜31˚˟ʬࡈ˜Ԩೌ̈ତ༼ˀ྇ ࡰආБᗇՎʹ׸ٙ዁ς๟ۆٙઋرf

REVIEW OF INTERIM RESULTS

The Audit Committee, which comprises three independent non-executive Directors, namely Mr. Lee Luen Wai, John BBS JP (Chairman), Dr. Li Kwok Tung, Donald SBS JP and Mr. Yeung Wing Sun, Mike, has reviewed, together with the management of the Company, the unaudited interim results of the Group for the six months ended 31 December 2020 and considered that they were prepared in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that the Company has made appropriate disclosure thereof.

審閱中期業績

ᄲࣨ։ࡰึ͟ɧΤዹͭڢੂБ໨ԫଡ଼ϓdу ҽᑌਃ΋͛€ზഓঠ݋௝d˄̻୛ɻ€˴ࢩeҽ਷ ಊᔼ͛€ვഓঠ݋௝e˄̻୛ɻʿเ࿲⮹΋͛d־ ഃʊၾ͉ʮ̡၍ଣᄴᄲቡ͉ණྠ࿚Ї2020ϋ 12˜31˚˟ʬࡈ˜ٙ͊຾ᄲࣨʕಂุᐶdԨ Ⴉމ༈ഃʕಂุᐶʊ࣬ኽϞᗫึࠇ๟ۆeɪ ̹஝ۆʿቇ͜جܛ஝֛ᇜႡd˲͉ʮ̡ʊЪ ̈ቇ຅מᚣf

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 31 December 2020, the interests and short positions of the Directors and Chief Executive of the Company in the shares, underlying shares and/or debentures (as the case may be) of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO) or which were required to be entered into the register required to be kept by the Company under section 352 of the SFO or which were otherwise required to be notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code were set out below:

董事及最高行政人員於股份、相 關股份及債權證的權益及淡倉

׵2020ϋ12˜31˚d໨ԫʿ͉ʮ̡௰৷Б݁ ɛࡰ׵͉ʮ̡אՉ΂О޴ᑌجྠ€່֛ԈᗇՎ ʿಂ஬ૢԷୋXV ௅ʘٰ΅e޴ᗫٰ΅ʿŊ אවᛆᗇ€ൖ˷ઋرϾ֛ʕdኹϞ࣬ኽᗇՎ ʿಂ஬ૢԷୋXV௅ୋ7ʿୋ8ʱ௅Ͼ඲ٝึ͉ ʮ̡ʿ࠰ಥᑌʹהʘᛆूʿ૱ࡑ€ܼ̍־ഃ࣬ ኽ༈ഃᗇՎʿಂ஬ૢԷૢ˖Ͼ஗ൖЪא຅Ъ ኹϞʘᛆूʿ૱ࡑdא࣬ኽᗇՎʿಂ஬ૢԷ ୋ352ૢ඲া፽׵͉ʮ̡πໄʘ೮াΤ̅ʫʘ ᛆूʿ૱ࡑdא࣬ኽᅺ๟ςۆϾ඲ٝึ͉ʮ ̡ʿ࠰ಥᑌʹהʘᛆूʿ૱ࡑνɨj

(I)The Company

(I)

本公司

Name of Director 董事姓名

Long/short position 好倉╱淡倉

Dr. Sun Yiu Kwong ࢑ᘴϪᔼ͛

Long position λࡑ

Long position λࡑ

Long position λࡑ

Long position λࡑ

Capacity 身份

Number of Shares/ underlying shares 股份╱相關股份數目

Beneficial owner 17,548,000 ྼूኹϞɛ

Notes 附註

Interest held by his 248,463,278 1 controlled corporations ᛆू͟ՉછՓجྠܵϞ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

700,000 3

2,300,000 4

Approximate percentage of shareholding 概約持股比例

(%)

269,011,278

35.13

Ms. Kwok Cheuk Kwan, Jacquen ெՙёɾɻ

Long position λࡑ

Long position λࡑ

Long position λࡑ

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

17,948,657

11,380,000 2

500,000 3

1,500,000 4

31,328,657

4.09

Name of Director 董事姓名

Long/short position 好倉╱淡倉

Mr. Tsang On Yip, Patrick ಀτุ΋͛

Long position λࡑ

Long position λࡑ

Long position λࡑ

Long position λࡑ

Capacity 身份

Number of Shares/ underlying shares 股份╱相關股份數目

Beneficial owner 100,000 ྼूኹϞɛ

Notes 附註

Beneficial owner 600,000 2 ྼूኹϞɛ

Beneficial owner 400,000 3 ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

1,500,000 4

Approximate percentage of shareholding 概約持股比例

(%)

2,600,000

0.34

Dr. Sun Man Kin, Michael ࢑˖਺ᔼ͛

Long position λࡑ

Long position λࡑ

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

16,142,000

400,000 3

1,500,000 4

18,042,000

2.36

Mr. Lee Kar Chung, Felix ҽ࢕ᑋ΋͛

Long position λࡑ

Long position λࡑ

Long position λࡑ

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

1,388,000

10,242,000 2

500,000 3

1,500,000 4

13,630,000

1.78

Dr. Lee Pak Cheung, Patrick ҽݡୂᔼ͛

Long position λࡑ

Long position λࡑ

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

20,042,959

400,000 3

1,500,000 4

21,942,959

2.87

ApproximateName of Director 董事姓名

Long/short position 好倉╱淡倉

Mr. Lee Luen Wai, John BBS JP ҽᑌਃ΋͛€ზഓঠ݋௝d˄̻୛ɻ

Long position λࡑ

Long position λࡑ

Capacity 身份

Number of Shares/ underlying shares 股份╱相關股份數目

Beneficial owner 220,000 ྼूኹϞɛ

Beneficial owner 300,000 ྼूኹϞɛ

Notes 附註

percentage of shareholding 概約持股比例

(%)

4

520,000

0.07

Dr. Li Kwok Tung, Donald SBS JP ҽ਷ಊᔼ͛€ვഓঠ݋௝d˄̻୛ɻ

Long position λࡑ

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

328,000

300,000

4

628,000

0.08

Mr. Yeung Wing Sun, Mike เ࿲⮹΋͛

Long position λࡑ

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Beneficial owner ྼूኹϞɛ

Notes:

• (1) Dr. Sun Yiu Kwong was deemed to be interested in the 203,457,278 Shares held by East Majestic Group Limited, being his controlled corporation, and was also deemed to be interested in 45,006,000 Shares held by EM Team Limited, also being his controlled corporation.

• (2) These Shares represented the underlying Shares under the options granted by the Company on 18 August 2015 pursuant to the Pre-IPO Share Option Scheme.

• (3) These Shares represented the share award granted by the Company on 17 July 2018 pursuant to the Share Award Scheme.

• (4) These Shares represented the underlying Shares under the options granted by the Company on 6 November 2018 pursuant to the Post-IPO Share Option Scheme.

20,000

200,000

4

220,000

0.03

ڝൗj

• (1) ࢑ᘴϪᔼ͛஗ൖމ׵־છՓʘجྠ East Majestic Group Limited ܵϞٙ 203,457,278ٰٰ΅ʕኹϞᛆूf࢑ᘴϪ ᔼ͛͵஗ൖމ׵Νᅵމ־છՓʘجྠ EM Team Limited ܵϞٙ 45,006,000 ٰٰ΅ ʕኹϞᛆूf

• (2) ༈ഃٰ΅ܸ͉ʮ̡׵2015ϋ8˜18˚࣬ኽ ࠯ϣʮක೯ਯۃᒅٰᛆࠇྌબ̈ٙᒅٰ ᛆධɨٙ޴ᗫٰ΅f

• (3) ༈ഃٰ΅ܸ͉ʮ̡׵2018ϋ7˜17˚࣬ኽ ٰ΅ᆤᎸࠇྌબٰ̈ٙ΅ᆤᎸධɨٙ޴ ᗫٰ΅f

• (4) ༈ഃٰ΅ܸ͉ʮ̡׵2018ϋ11˜6˚࣬ኽ ࠯ϣʮක೯ਯܝᒅٰᛆࠇྌબ̈ٙᒅٰ ᛆධɨٙ޴ᗫٰ΅f

(II) Associated Corporations (within the meaning of the SFO)

Procare Medical Imaging & Laboratory Centre Limited(1)Long/short

(II) 相聯法團（定義見證券及期貨條例）

普康醫學影像及化驗中心有限公司(1)

銅鑼灣磁力共振中心有限公司(2)

Long/short

(1) UMP Medical Centre Limited, a wholly-owned subsidiary of the

Company, holds 62.5% of the entire issued share capital of Procare Medical Imaging & Laboratory Centre Limited.

(2)UMP Medical Centre Limited, a wholly-owned subsidiary of the Company, holds 20% of the entire issued share capital of Causeway Bay MRI Centre Limited.

Number of percentage of shares shareholding 股份數目 概約持股比例

Approximate

(%)

625

6.25

Approximate

Number of percentage of shares shareholding 股份數目 概約持股比例

(%)

95

6.33

• (1) ͉ʮ̡ٙΌ༟ڝ᙮ʮ̡ᑌΥᔼਕʕːϞ ࠢʮ̡ܵϞ౷ੰᔼኪᅂ྅ʿʷ᜕ʕːϞ ࠢʮ̡ٙΌ௅ʊ೯Бٰ͉ٙ62.5%f

• (2) ͉ʮ̡ٙΌ༟ڝ᙮ʮ̡ᑌΥᔼਕʕːϞ ࠢʮ̡ܵϞზ᝟ᝄှɢ΍ࣈʕːϞࠢʮ ̡ٙΌ௅ʊ೯Бٰ͉ٙ20%f

Name of Director 董事姓名

Details of Change 變動詳情

Dr. Li Kwok Tung, Donald SBS JP

ҽ਷ಊᔼ͛€ვഓঠ݋௝d˄̻୛ɻ

Dr. Li was appointed as an independent non-executive director of Sino Biopharmaceutical Limited, a company incorporated in Cayman Islands with limited liability, the shares of which are listed on the main board of Stock Exchange (stock code: 1177), on 31 December 2020. ҽᔼ͛׵2020ϋ12˜31˚ᐏ։΂މʕ਷͛يႡᖹϞࠢʮ̡€ɓ࢕׵කਟ໊ࢥൗ ̅ϓͭٙϞࠢʮ̡dՉٰ΅׵ᑌʹה˴ؐɪ̹€ٰ΅˾໮j 1177 ٙዹͭڢੂ Б໨ԫf

SHARE OPTION SCHEMES

The Company has adopted two share option schemes, namely the Pre-IPO Share Option Scheme and the Post-IPO Share Option Scheme.

購股權計劃

͉ʮ̡ʊમॶՇධᒅٰᛆࠇྌdу࠯ϣʮක ೯ਯۃᒅٰᛆࠇྌʿ࠯ϣʮක೯ਯܝᒅٰᛆ ࠇྌf

Grantee

承授人

Directors 董事

Ms. Kwok Cheuk Kwan, Jacquen ெՙёɾɻ

Mr. Tsang On Yip, Patrick ಀτุ΋͛

Mr. Lee Kar Chung, Felix ҽ࢕ᑋ΋͛

Employees 僱員

In aggregate

Υ΍

Other eligible grantees 其他合資格承授人

In aggregate

Υ΍

Position

Date of grant

職位

授出日期

(dd/mm/yy)

€˚Ŋ˜Ŋϋ

Managing Director and Executive Director ໨ԫᐼ຾ଣࡒੂБ໨ԫ

18/08/2015

Executive Director

18/08/2015

ੂБ໨ԫ

Executive Director

18/08/2015

ੂБ໨ԫ

-

18/08/2015

-

18/08/2015

Exercise price per ShareExercise period

每股行使價

行使期

(HK$)

(dd/mm/yy)

€ಥʩ €˚Ŋ˜Ŋϋ

1.2228

18/08/2016-26/11/2022 18/08/2017-26/11/2022

1.2228

18/08/2016-26/11/2022 18/08/2017-26/11/2022

As at 1 July 2020 於2020年 7月1日

1,138,000 - - - 1,138,000

10,242,000

60,000 - - - 60,000

540,000 - - - 540,000

1.2228

• 18/08/2017-26/11/2022 10,242,000

Sub-total: ʃࠇj

1.2228

18/08/2017-26/11/2022

22,222,000

3,186,000 - - - 3,186,000

Sub-total: ʃࠇj

3,186,000

1.2228

• 18/08/2016-26/11/2022 160,000

• 18/08/2017-26/11/2022 1,440,000

Sub-total: ʃࠇjTotal: ᐼࠇj

As at 31 December 2020 於2020年 12月31日

-

-

- 10,242,000

-

-

- 10,242,000

-

-

- 22,222,000

-

-

-

3,186,000

- -

- -

- -

160,000 1,440,000

1,600,000

-

-

-

1,600,000

27,008,000

-

-

-

27,008,000

As at 31 December 2020, 27,008,000 options remained outstanding under the Pre-IPO Share Option Scheme.

׵2020ϋ12˜31 ˚d࠯ϣʮක೯ਯۃ ᒅٰᛆࠇྌධɨϞ27,008,000΅ᒅٰᛆ ֠͊БԴf

Grantee 承授人

Directors 董事

Dr. Sun Yiu Kwong ࢑ᘴϪᔼ͛

Ms. Kwok Cheuk Kwan, Jacquen ெՙёɾɻ

Mr. Tsang On Yip, Patrick ಀτุ΋͛

Dr. Sun Man Kin, Michael ࢑˖਺ᔼ͛

Mr. Lee Kar Chung, Felix ҽ࢕ᑋ΋͛

Dr. Lee Pak Cheung, Patrick ҽݡୂᔼ͛

Mr. Lee Luen Wai, John BBS JP ҽᑌਃ΋͛€ზഓঠ݋௝d˄̻୛ɻ

Position 職位

Chairman, Chief Executive Officer and Executive Director ˴ࢩeБ݁ᐼ൒ࡒ ੂБ໨ԫ

Managing Director and Executive Director ໨ԫᐼ຾ଣࡒੂБ໨ԫ

Executive Director

ੂБ໨ԫ

Executive

ੂБ໨ԫ

Director

ExecutiveDirector

ੂБ໨ԫ

Executive Director

ੂБ໨ԫ

Independent

Non-executive Director ዹͭڢੂБ໨ԫ

Dr. Li Kwok Tung, Donald SBS JP Independent

ҽ਷ಊᔼ͛€ვഓঠ݋௝d˄̻୛ɻ

Mr. Yeung Wing Sun, Mike เ࿲⮹΋͛

Non-executive Director ዹͭڢੂБ໨ԫ

Independent

Non-executive Director ዹͭڢੂБ໨ԫ

Date of grant 授出日期

Exercise price per Share Exercise period 每股行使價 行使期

(dd/mm/yyyy)

(HK$) dd/mm/yyyy)

€˚Ŋ˜Ŋϋ

€ಥ ʩ €˚Ŋ˜Ŋϋ

(B)

As at 1 July 2020 於2020年 7月1日

Granted during the period 期內已授出

Exercised during the period 期內已行使

As at 31 December 2020 於2020年 12月31日

06/11/2018

2.06 30/06/2019

- 05/11/2023

2,300,000 - - - 2,300,000

06/11/2018

• 2.06 30/06/2019

  - 05/11/2023

  1,500,000 - - - 1,500,000

  06/11/2018

• 2.06 30/06/2019

  - 05/11/2023

  1,500,000 - - - 1,500,000

  06/11/2018

• 2.06 30/06/2019

  - 05/11/2023

  1,500,000 - - - 1,500,000

  06/11/2018

• 2.06 30/06/2019

  - 05/11/2023

  1,500,000 - - - 1,500,000

  06/11/2018

• 2.06 30/06/2019

  - 05/11/2023

  1,500,000 - - - 1,500,000

  06/11/2018

• 2.06 30/06/2019

  - 05/11/2023

  300,000 - - - 300,000

  06/11/2018

• 2.06 30/06/2019

  - 05/11/2023

  300,000 - - - 300,000

  06/11/2018

• 2.06 30/06/2019

  - 05/11/2023

200,000 - - - 200,000

Sub-total 小計

10,600,000

-

-

-

10,600,000

Cancelled/LapsedAs atGrantee 承授人

Employees 僱員

In aggregate

Υࠇ

Other eligible grantee(s)

其他合資格承授人

In aggregate

Υࠇ

Position 職位

€˚Ŋ˜Ŋϋ

Date of grant 授出日期

(dd/mm/yyyy)

06/11/2018

05/05/2019

05/05/2019

05/05/2019

23/03/2017

23/03/2017

06/11/2018

05/05/2019

05/05/2019

05/05/2019

• 2.06 30/06/2017

  - 29/06/2022

• 2.06 30/06/2018

  - 29/06/2022

• 2.06 30/06/2019

  - 05/11/2023

• 1.56 04/05/2020

  - 03/05/2025

• 1.56 04/05/2021

  - 03/05/2025

• 1.56 04/05/2022

  - 03/05/2025

  Sub-total 小計

• 2.06 30/06/2019

  - 05/11/2023

• 1.56 04/05/2020

  - 03/05/2025

• 1.56 04/05/2021

  - 03/05/2025

• 1.56 04/05/2022

  - 03/05/2025

  Sub-total 小計

  Total 總計

As at 31 December 2020, none of options granted under the Post-IPO Share Option Scheme during the six months ended 31 December 2020.

׵2020ϋ12˜31 ˚d฿ೌ࣬ኽ࠯ϣʮ ක೯ਯܝᒅٰᛆࠇྌ׵࿚Ї2020ϋ12˜ 31˚˟ʬࡈ˜બ̈ᒅٰᛆf

SHARE AWARD SCHEME

The Company has adopted the Share Award Scheme on 30 June 2016 to recognise the contributions of and provide incentives for the key management personnel including Directors and senior management, employed experts and employees of the Group.

Subject to any early termination as may be determined by the Board, pursuant to the trust deed, the Share Award Scheme shall be valid and effective for a term of 10 years commencing on the adoption date. The maximum number of Shares which may be awarded to a selected participant under the Share Award Scheme shall not exceed 1% of the issued share capital of the Company in each year.

The Board shall not make any further award of the awarded Shares which will result in the nominal value of the Shares awarded by the Board under the Share Award Scheme exceeding 2% of the issued share capital of the Company from time to time.

股份獎勵計劃

͉ʮ̡ʊ׵ 2016ϋ6˜30 ˚મॶٰ΅ᆤᎸࠇ ྌdྗᆤʿᆤᎸ˴ࠅ၍ଣɛࡰ€ܼ̍໨ԫʿ ৷ॴ၍ଣᄴe͉ණྠա྇ਖ਼࢕ʿ྇ࡰהЪ ্ᘠfա໨ԫึ̙ঐᔾ֛ٙ΂О౤ۃ୞˟ה ࠢd࣬ኽڦৄ۰ኽdٰ΅ᆤᎸࠇྌ׵મॶ˚ ಂৎࠇɤϋಂගϞࣖʿ͛ࣖf࣬ኽٰ΅ᆤᎸ ࠇྌ̙બʚ፯֛ਞၾ٫ٰٙ΅ᅰͦɪࠢʔ੻ ൴ཀ͉ʮ̡΢ϋʊ೯Бٰ͉ٙ1%f໨ԫึʔ ੻બ̈΂Оึኬߧ໨ԫึ࣬ኽٰ΅ᆤᎸࠇྌ બ̈൴ཀ͉ʮ̡ʔࣛʊ೯Бٰ͉2%ʘٰ΅ࠦ ࠽ٙආɓӉᆤᎸٰ΅f

Details of the share award granted and outstanding under the Share Award Scheme are set out as follows:

ٰ΅ᆤᎸࠇྌධɨʊબ̈ʿ֠͊БԴʘٰ΅ ᆤᎸ༉ઋ༱ΐνɨj

Name or category of participant 參與人姓名或類別

As at 1 July 2020 於2020年7月1日

Granted during the period 期內授出

Vested during the period 期內歸屬

Cancelled/lapsed during the period 期內註銷╱失效

As at 31 December 2020 於2020年12月31日

Directors ໨ԫ

2,900,000

-

-

-

2,900,000 (Note 1) €ڝൗ1

Other eligible grantee(s)

Չ˼Υ༟ࣸוબɛ

In aggregate 總計

400,000

2,330,000

-

-

5,630,000

-

-

-

-

-

-

400,000

(Note 1)

€ڝൗ1

2,330,000

(Note 1)

€ڝൗ1

-

5,630,000

Note:

ڝൗj

Certain Shares have been purchased and no Shares have been granted under the Share Award Scheme during the period and none of shares have been vested during the period up to 31 December 2020.

ಂʫʊ࣬ኽٰ΅ᆤᎸࠇྌᒅ൯߰ʍٰ΅ʿԨ ೌબٰ̈΅dٜЇ2020ϋ12˜31˚˟ಂගԨ ೌٰ΅ᓥ᙮f

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 31 December 2020, so far as was known to the Directors of the Company, the following persons/entities (other than the Directors or Chief Executive of the Company) had, or were deemed to have, interests or short positions in the Shares or underlying shares of the Company which would fall to be disclosed to the Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO:

主要股東於本公司股份及相關股 份的權益及淡倉

׵2020ϋ12˜31˚dኽ͉ʮ̡໨ԫהٝd˸ ɨɛɻŊྼ᜗€໨ԫא͉ʮ̡௰৷Б݁ɛࡰৰ ̮׵͉ʮ̡ʘٰ΅א޴ᗫٰ΅ʕኹϞא஗ൖ މኹϞ˸ɨᛆूא૱ࡑϾ඲࣬ኽᗇՎʿಂ஬ ૢԷୋXV௅ୋ2ʿ3ʱ௅ૢ˖඲Σ͉ʮ̡ʿ࠰ ಥᑌʹהמᚣdאা፽׵͉ʮ̡඲࣬ኽᗇՎ ʿಂ஬ૢԷୋ336ૢπໄʘ೮াΤ̅ʫj

Name of substantial shareholder

主要股東姓名╱名稱

East Majestic Group LimitedEM Team Limited

Cheng Yu Tung Family

(Holdings II) LimitedCheng Yu Tung Family

(Holdings) Limited

Chow Tai Fook Capital LimitedChow Tai Fook (Holding) Limited մɽ၅€છٰϞࠢʮ̡

Chow Tai Fook Enterprises Limited մɽ၅ΆุϞࠢʮ̡

Healthcare Ventures

China Resources Company Limited ʕ਷ശᆗϞࠢʮ̡

Long/short position

好倉╱淡倉

Capacity

身份

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Long position λࡑ

Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ

Long position λࡑ

Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ

Long position λࡑ

Interest held by its controlled corporation ᛆू͟ՉછՓجྠܵϞ

Long position λࡑ

Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ

Long position λࡑ

Interest held by its controlled corporation ᛆू͟ՉછՓجྠܵϞ

Long position λࡑ

Beneficial owner ྼूኹϞɛ

Long position λࡑ

Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ

CR Medical ശᆗᔼᐕ

Long position λࡑ

Interest held by its controlled corporations ᛆू͟ՉછՓجྠܵϞ

Number of Shares/ underlying shares

股份╱相關股份數目

Interests under equity derivatives 股本衍生工具 項下之權益

NotesApproximate percentage of shareholding

附註

概約持股比例

(%)

203,457,278 - 1 26.57

45,006,000 - 1 5.88

112,687,939 - 2 14.72

112,687,939 - 2 14.72

112,687,939 - 2 14.72

112,687,939 - 2 14.72

112,687,939 - 2 14.72

112,687,939 - 2 14.72

91,803,000 - 3 11.99

91,803,000 - 3 11.99

Notes:

• 1. Dr. Sun Yiu Kwong was deemed to be interested in the 203,457,278 Shares held by East Majestic Group Limited, being his controlled corporation, and was also deemed to be interested in the 45,006,000 Shares held by EM Team Limited, also being his controlled corporation. Dr. Sun's interests in Shares are disclosed in this interim report in the section headed "Directors' and Chief Executive interests and Short Positions in Shares, Underlying Shares and Debentures".

• 2. Healthcare Ventures was wholly owned by Chow Tai Fook Enterprises Limited ("CTFE"), which was wholly owned by Chow Tai Fook (Holding) Limited ("CTFH"). So far as the Company is aware, CTFH was held as to 81.03% by Chow Tai Fook Capital Limited ("CTFC"), which was in turn held as to 48.98% by Cheng Yu Tung Family (Holdings) Limited ("CYTF") and as to 46.65% by Cheng Yu Tung Family (Holdings II) Limited ("CYTFII"). By virtue of the SFO, CTFE, CTFH, CTFC, CYTF and CYTFII were deemed to be interested in the same parcel of Shares in which Healthcare Ventures was interested.

• 3. Pinyu Limited was the beneficial owner of the Shares. Pinyu Limited was wholly owned by Unison Champ Premium Limited, which was wholly owned by CR Medical. CR Medical was held as to 35.76% by CRH (Medical) Limited and as to 0.82% by Commotra Company Limited. CRH (Medical) Limited was wholly owned by China Resources Healthcare Group Limited, which was wholly owned by CRH (Healthcare) Limited. Both CRH (Healthcare) Limited and Commotra Company Limited were wholly owned by China Resources (Holdings) Company Limited, which was wholly owned by CRC Bluesky Limited. CRC Bluesky Limited was wholly owned by China Resources INC, which was wholly owned by China Resources Company Limited. By virtue of the SFO, Unison Champ Premium Limited, CR Medical, CRH (Medical) Limited, China Resources Healthcare Group Limited, CRH (Healthcare) Limited, China Resources INC, China Resources (Holdings) Company Limited, CRC Bluesky Limited and China Resources Company Limited were deemed to be interested in the same parcel of Shares in which Pinyu Limited was interested.

ڝൗj

• 1. ࢑ᘴϪᔼ͛஗ൖމ׵־છՓʘجྠ East Majestic Group LimitedܵϞٙ203,457,278ٰٰ΅ʕኹ Ϟᛆूf࢑ᔼ͛͵஗ൖމ׵Νᅵ͟־છՓʘج ྠ EM Team LimitedܵϞٙ45,006,000ٰٰ΅ʕ ኹϞᛆूf࢑ᔼ͛׵ٰ΅ʘᛆूʊ׵͉ʕಂజ ѓ˜໨ԫʿ௰৷Б݁ɛࡰ׵ٰ΅e޴ᗫٰ΅ʿව ᛆᗇٙᛆूʿ૱ࡑ™ɓືמᚣf

• 2. ᔼᐕ௴ุછٰ͟մɽ၅ΆุϞࠢʮ̡€˜մɽ၅ Άุ™Ό༟ኹϞdϾմɽ၅Άุ͟մɽ၅€છ ٰϞ ࠢ ʮ ̡€˜ CTFH ™Ό༟ኹϞfఱ͉ʮ̡ הٝdCTFH͟Chow Tai Fook Capital Limited €˜ CTFC ™ܵ Ϟ81.03% ٰٙᛆdϾ CTFC ʱй ͟Cheng Yu Tung Family (Holdings) Limited €˜CYTF™ʿCheng Yu Tung Family (Holdings

  II) Limited€˜ CYTFII ™ܵ Ϟ48.98%ʿ46.65% ٰٙᛆf࣬ኽᗇՎʿಂ஬ૢԷdմɽ၅Άุe CTFHeCTFCeCYTFʿCYTFII஗ൖމ׵ᔼᐕ௴ ุછٰኹϞᛆूٙΝɓҭٰ΅ʕኹϞᛆूf

• 3. ۜ༃Ϟࠢʮ̡މٰ΅ʘྼूኹϞɛfۜ༃Ϟ ࠢʮ̡͟ Unison Champ Premium LimitedΌ ༟ኹϞdϾUnison Champ Premium Limited͟ ശᆗᔼᐕΌ༟ኹϞfശᆗᔼᐕ͟ശᆗණྠ€ᔼ ᐕϞࠢʮ̡ኹϞ 35.76%˸ʿ͟Υ൱Ϟࠢʮ̡ ኹϞ0.82% fശᆗණྠ€ᔼᐕϞࠢʮ̡͟ശᆗ ਄ੰණྠϞࠢʮ̡Ό༟ኹϞdϾശᆗ਄ੰණྠ Ϟࠢʮ̡͟ശᆗණྠ€਄ੰϞࠢʮ̡Ό༟ኹ Ϟfശᆗණྠ€਄ੰϞࠢʮ̡ʿΥ൱Ϟࠢʮ ̡ѩ͟ശᆗ€ණྠϞࠢʮ̡Ό༟ኹϞdϾശ ᆗ€ණྠϞࠢʮ̡͟ CRC Bluesky LimitedΌ ༟ኹϞfCRC Bluesky Limited͟ശᆗٰ΅Ϟࠢ ʮ̡Ό༟ኹϞdϾശᆗٰ΅Ϟࠢʮ̡͟ʕ਷ശ ᆗϞࠢʮ̡Ό༟ኹϞf࣬ኽᗇՎʿಂ஬ૢԷd Unison Champ Premium Limitedeശᆗᔼᐕe ശᆗණྠ€ᔼᐕϞࠢʮ̡eശᆗ਄ੰණྠϞࠢ ʮ̡eശᆗණྠ€਄ੰϞࠢʮ̡eശᆗٰ΅Ϟ ࠢʮ̡eശᆗ€ණྠϞࠢʮ̡e CRC Bluesky Limitedʿʕ਷ശᆗϞࠢʮ̡஗ൖމ׵ۜ༃Ϟࠢ ʮ̡ኹϞᛆूٙΝɓҭٰ΅ʕኹϞᛆूf

According to disclosure of interest filings available on the Stock Exchange website, Snow Lake China Master Fund, Ltd. ("SLCMF") and Snow Lake China Master Long Fund, Ltd. ("SLCMLF") beneficially owned 100,000,000 and 20,640,000 Shares respectively. Snow Lake Capital (HK) Limited ("SLCHKL"), which was wholly controlled by Mr. Ma Sean, was the investment manager to both SLCMF and SLCMLF respectively. Accordingly, Mr. Ma Sean and SLCHKL were deemed to be interested in aggregate holding of 120,640,000 Shares owned by SLCMF and SLCMLF pursuant to the SFO, representing, for illustrative purpose, 15.75% of the total issued share capital of the Company as at 31 December 2020. Out of these 120,640,000 Shares, 86,984,000 Shares (representing, for illustrative purpose, 11.36% of the total issued share capital of the Company as at 31 December 2020) are interests in cash-settled equity derivatives.

Other than as disclosed above, as at 31 December 2020, the Directors have not been notified by any person (other than the Directors or Chief Executive of the Company) who had interests or short positions in the Shares or underlying shares of the Company as recorded in the register required to be kept pursuant to Section 336 of the SFO.

࣬ኽᑌʹהၣ१̙੻ٙᛆूמᚣ༟ࣘdSnow Lake China Master Fund, Ltd€. ˜SLCMF™ʿ Snow Lake China Master Long Fund, Ltd. €˜ SLCMLF ™ʱйྼूኹϞ 100,000,000 ٰʿ 20,640,000 ٰٰ΅f͟৵Іთ΋͛Ό ༟છՓٙ Snow Lake Capital (HK) Limited €˜SLCHKL™މSLCMFʿSLCMLFʘҳ༟၍ଣ ɛfΪϤd࣬ኽᗇՎʿಂ஬ૢԷd৵Іთ΋ ͛ʿSLCHKL஗ൖމ׵SLCMFʿSLCMLFΥ΍ ܵϞʘ120,640,000 ٰٰ΅ʕኹϞᛆू€සԶ Ⴍ׼͜௄d޴຅׵2020ϋ12˜31˚͉ʮ̡ʊ ೯Бٰ͉ᐼᕘ15.75%)f׵༈120,640,000ٰ ٰ΅ʕd86,984,000ٰٰ΅€සԶႭ׼͜௄d ޴຅׵2020ϋ12˜31˚͉ʮ̡ʊ೯Бٰ͉ᐼ ᕘ11.36%މ׵˸ତږഐၑٰᛆࠃ͛ʈՈʘ ᛆूf ৰɪ˖מᚣ̮d׵2020ϋ12˜31˚d໨ԫԨ ೌٝ઄΂Оɛɻ€໨ԫא͉ʮ̡௰৷Б݁ɛࡰ ৰ̮׵͉ʮٰ̡΅א޴ᗫٰ΅ʕኹϞ࣬ኽᗇ Վʿಂ஬ૢԷୋ336ૢ඲πໄٙ೮াΤ̅הা ፽ٙᛆूא૱ࡑf

INTERIM DIVIDEND

The Board declared an interim dividend of HK1.00 cent (the corresponding period in 2019: HK0.65 cent) per Share for the six months ended 31 December 2020.

中期股息

໨ԫึݼ˹࿚Ї2020ϋ12˜31˚˟ʬࡈ˜ٙ ʕಂٰࢹӊٰ1.00ಥ̀€2019ϋΝಂj0.65ಥ ̀f

The interim dividend will be payable to the shareholders of the Company whose names appear on the register of members of the Company on Thursday, 18 March 2021. It is expected that the interim dividend will be paid on or about Friday, 9 April 2021.

ʕಂٰࢹਗ਼ݼ˹ʚ׵ 2021ϋ3˜18˚€݋ ಂ ̬Τΐ͉ʮٰ̡؇Τ̅ɪʘ͉ʮٰ̡؇fཫ ಂʕಂٰࢹਗ਼׵2021ϋ4˜9˚€݋ಂʞאۃ ܝݼ˹f

CLOSURE OF REGISTER OF MEMBERS

Book close dates

(both days inclusive)

Latest time to lodge transfer with share registrar

• : Tuesday, 16 March 2021 to Thursday, 18 March 2021

• : 4:30 p.m. on Monday,

  15 March 2021

  暫停辦理股份過戶手續

  ᅲ৾፬ଣٰ΅ཀ˒	j	2021ϋ3˜16˚€݋ ಂ ɚЇ
  ೮া˚ಂ€࠯҈	2021ϋ3˜18˚€݋ ಂ ̬
  Շ˂ܼ̍ίʫ
  ٰ΅ཀ˒೮া࿚˟	j	2021ϋ3˜15˚€݋ ಂ ɓd
  ፬ଣٰ΅ཀ˒	ɨʹ̬ࣛɧɤʱ

  ٰ΅ཀ˒೮াήᓃ j ࠰ಥٰ΅ཀ˒೮াʱஈ
  ՙԳᗇՎ೮াϞࠢʮ̡
  ࠰ಥ
  ެΧɽ༸؇183໮
  Υձʕː54ᅽ
  PURCHASE, SALE OR REDEMPTION OF THE	購買、出售或贖回本公司上市證
  COMPANY'S LISTED SECURITIES	券
  During the six months ended 31 December 2020, neither the	࿚Ї2020ϋ12˜31˚˟ʬࡈ˜d͉ʮ̡ʿ͉
  Company nor any of its subsidiaries has purchased, sold or	ʮ̡΂Оڝ᙮ʮ̡฿ೌᒅ൯ëਯאᛙΫ͉
  redeemed any of the Company's listed securities.	ʮ̡΂Оɪ̹ᗇՎf
  SUFFICIENCY OF THE PUBLIC FLOAT	足夠公眾持股量
  Based on the information publicly available to the Company and	ఱ͉ʮ̡ה੻ʘʮක༟ࣘהͪdԨኽ໨ԫה
  to the best knowledge, information and belief of the Directors, the	ଉٝeה઄ʿהڦd໨ԫᆽႩ࿚Ї2020ϋ12
  Directors confirm that the Company had maintained a sufficient	˜31˚˟ʬࡈ˜͉ʮ̡ʊၪܵɪ̹஝ۆה஝
  public float as required under the Listing Rules during the six months	֛ʘ̂ԑʮ଺ٰܵඎf
  ended 31 December 2020.
  On behalf of the Board	˾ڌ໨ԫึ
  Dr. Sun Yiu Kwong	孫耀江醫生
  Chairman and Chief Executive Officer	˴ࢩࡒБ݁ᐼ൒
  Hong Kong, 25 February 2021	࠰ಥd2021ϋ2˜25˚

  Address of share registrar

• : Hong Kong Branch Share Registrar Tricor Investor Services Limited Level 54, Hopewell Centre 183 Queen's Road East

  Hong Kong

Condensed Consolidated Statement of Profit or Loss 簡明綜合損益表

Six months ended 31 December 2020

࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜

Six months ended 31 December 截至12月31日止六個月

Condensed Consolidated Statement of Comprehensive Income 簡明綜合全面收入表

Six months ended 31 December 2020 ࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜

PROFIT FOR THE PERIOD

期內利潤

Six months ended 31 December 截至12月31日止六個月

2020 2020年 HK$'000 千港元

(Unaudited)

（未經審核）

2019 2019ϋ HK$'000 ɷಥʩ

(Unaudited)

€͊຾ᄲࣨ

49,166

OTHER COMPREHENSIVE INCOME/(LOSS)

Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:

Exchange differences on translation of foreign operations

Share of other comprehensive loss of an associate

Reclassification adjustments for amount transferred to profit or loss on disposal of a subsidiary

其他全面收入╱（虧損）

׵Չܝಂග̙ঐࠠอʱᗳЇฦू

ٙՉ˼ΌࠦϗɝŊ€ᑦฦj ұၑऎุ̮ਕٙිгࢨᕘ ʱЦɓගᑌᐄʮ̡ٙՉ˼Όࠦ ᑦฦ ׵̈ਯɓගڝ᙮ʮ̡ࣛࠠอʱᗳ ሜ዆ᔷɝЇฦूʘږᕘ

Net other comprehensive income/(loss) that may ׵Չܝಂග̙ঐࠠอʱᗳЇฦूٙ

be reclassified to profit or loss in subsequent periods

Չ˼ΌࠦϗɝŊ€ᑦฦଋᕘ

2,494 (587)

- (18)

-

(605)Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:

Changes in fair value of equity investments designated at fair value through other comprehensive income

׵ՉܝಂගʔึࠠอʱᗳЇฦू

ٙՉ˼Όࠦᑦฦj ܸ֛މܲʮʪᄆ࠽ࠇɝՉ˼

Όࠦϗɝʘٰ͉ҳ༟ٙ ʮʪᄆ࠽ᜊਗ

(2,411) (11,376)

OTHER COMPREHENSIVE INCOME/(LOSS)

FOR THE PERIOD, NET OF TAX

期內其他全面收入╱（虧損），

扣除稅項

1,362 (11,981)

TOTAL COMPREHENSIVE INCOME

FOR THE PERIOD

期內全面收入總額

37,185

Attributable to:

Owners of the Company Non-controlling interests

˸ɨ΢˙ᏐЦj ͉ʮ̡ኹϞɛ ڢછٰᛆू

32,441 33,570

1,495 3,615

37,185

31 December 2020 2020 ϋ 12 ˜ 31˚

31 December 2020 2020 ϋ 12 ˜ 31˚

Condensed Consolidated Statement of Changes in Equity 簡明綜合權益變動表

Six months ended 31 December 2020

࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜

Attributable to owners of the Company 本公司擁有人應佔

Shares held for theShareCapitalIssued capitalpremium contributionaccountreserve

award scheme 就股份 獎勵計劃 持有的 股份

share Share-basedpayment reserve 以股份 為基礎 支付的 儲備

Fair value reserveLegal reserve

Exchange fluctuation reserveRetained profitsTotalNon-controlling interests

Total equity

已發行 股本

股份 溢價賬

出資 儲備

公允 價值儲備

法定儲備

匯兌波動 儲備

留存 利潤

合計

非控股 權益

權益 總額

Notes ڝൗ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

HK$'000 ɷಥʩ

At 1 July 2019

ಂʫлᆗ

(unaudited and restated) Profit for the period

Other comprehensive income/(loss) ಂʫՉ˼ΌࠦϗɝŊfor the period:

Changes in fair value of equityinvestments at fair value through ɝʘٰ͉ҳ༟ٙʮʪᄆ࠽

other comprehensive incomeExchange differences on translation ұၑऎุ̮ਕٙිгࢨᕘ of foreign operations

Share of other comprehensive loss of an associate

ಂʫΌࠦϗɝŊ€ᑦฦ

Total comprehensive income/(loss)for the period

˸ᛆूഐၑʘτર

Equity-settled arrangementsDividends paid/payable to non-controlling interests Purchase of shares for the share award scheme

Acquisition of non-controlling interest

Disposal of a subsidiary Transfer to legal reserveAt 31 December 2019 (unaudited) ׵2019ϋ12˜31˚ €͊຾ᄲࣨ

׵2020ϋ6˜30 ˚€຾ᄲࣨ397,612*(13,430)*(22,301)*169,409*670,507

ಂʫлᆗ

At 30 June 2020 (audited) Profit for the period

Other comprehensive income/(loss) for the period: Changes in fair value of equityinvestments at fair value through ɝʘٰ͉ҳ༟ٙʮʪᄆ࠽

other comprehensive incomeExchange differences on translation ұၑऎุ̮ਕٙිгࢨᕘ of foreign operations

ಂʫΌࠦϗɝŊ€ᑦฦ

Reclassification adjustments for amount transferred to profit or loss on disposal of a subsidiary Total comprehensive income/(loss)for the period

˸ᛆूഐၑʘτર Dividends paid to non-controlling ʊ˹ڢછٰᛆूٙ

Equity-settled arrangementsinterests

Purchase of shares for the share award scheme

Final 2020 dividend Transfer to legal reserve At 31 December 2020 (unaudited)

*These reserve accounts comprise the consolidated reserves of HK$623,767,000 (30 June 2020: HK$611,080,000) in the condensed consolidated statement of financial position.

*

༈ഃᎷ௪ሪܼ̍׵ᔊ׼ၝΥৌਕًرڌʫʘ ၝΥᎷ௪ 623,767,000 ಥ ʩ€ 2020ϋ6˜30˚j 611,080,000ಥ ʩf

Condensed Consolidated Statement of Cash Flows 簡明綜合現金流量表

Six months ended 31 December 2020 ࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜

Six months ended 31 December 截至12月31日止六個月

Condensed Consolidated Statement of Cash Flows 簡明綜合現金流量表

Six months ended 31 December 2020

࿚Ї2020 ϋ 12 ˜ 31˚˟ʬࡈ˜

Six months ended 31 December 截至12月31日止六個月

• • corporate healthcare solution services;

• • medical and dental services;

• • medical imaging and laboratory services;

• • other auxiliary medical services; and

• • healthcare management services.

The shares of the Company were listed on the Main Board of the Hong Kong Stock Exchange on 27 November 2015 (the

2. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements of the Group for the six months ended 31 December 2020 have been prepared in accordance with the Hong Kong Accounting Standard ("HKAS") 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). They have been prepared under the historical cost convention, except for equity investments, debt investments and a contingent consideration receivable which have been measured at fair value. The unaudited condensed consolidated financial statements are presented in Hong Kong dollars and all values are rounded to the nearest thousand except when otherwise indicated.

• • Άุᔼᐕڭ਄༆Ӕ˙ࣩ؂ਕi

• • ᔼᐕʿ˫߅؂ਕi

• • ᔼኪᅂ྅ʿʷ᜕؂ਕi

• • Չ˼Ⴞпᔼᐕ؂ਕiʿ

• • ᔼᐕڭ਄၍ଣ؂ਕf ͉ʮٰ̡΅׵ 2015ϋ11˜27 ˚ί࠰ಥ ᑌʹה˴ؐɪ̹€˜ɪ̹™f

編製基準

͉ණྠ࿚Ї 2020ϋ12˜31 ˚˟ʬࡈ˜ ʘ͊຾ᄲࣨᔊ׼ၝΥৌਕజڌɗ࣬ኽ࠰ ಥึࠇࢪʮึ€˜࠰ಥึࠇࢪʮึ™཯б ٙ࠰ಥึࠇ๟ۆ€˜࠰ಥึࠇ๟ۆ™ୋ34 ໮˜ʕಂৌਕజѓ™ϾᇜႡfৰ˸ʮʪᄆ ࠽ࠇඎٰ͉ٙҳ༟eවਕҳ༟˸ʿᏐϗ אϞ˾ᄆ̮d͊຾ᄲࣨᔊ׼ၝΥৌਕజ ڌʊ࣬ኽዝ̦ϓ͉جᇜႡf͊຾ᄲࣨᔊ ׼ၝΥৌਕజڌ˸ಥʩяΐd˲ৰ̤Ϟ ܸ׼٫̮dהϞږᕘѩ̬વʞɝЇ௰ટ ڐٙɷЗᅰf

The unaudited condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 30 June 2020.

͊຾ᄲࣨᔊ׼ၝΥৌਕజڌԨʔܼ̍ϋ ܓৌਕజڌהცٙהϞ༟ࣘʿמᚣdԨ Ꮠၾ͉ණྠ࿚Ї2020ϋ6˜30˚˟ϋܓ ʘϋܓၝΥৌਕజڌɓԻቡᛘf

CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

3. 會計政策及披露變動

The accounting policies adopted in the preparation of the unaudited condensed consolidated financial statements of the Group for the six months ended 31 December 2020 are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 30 June 2020, except for the adoption of the following new and revised Hong Kong Financial Reporting Standards ("HKFRSs"), which are effective for the Group's annual period beginning on 1 July 2020.

ᇜႡ͉ණྠ࿚Ї 2020ϋ12˜31 ˚˟ʬ ࡈ˜ʘ͊຾ᄲࣨᔊ׼ၝΥৌਕజڌהમ ٙ͜ึࠇ݁ഄၾᇜႡ͉ණྠ࿚Ї 2020 ϋ6˜30˚˟ϋܓʘϋܓၝΥৌਕజڌ הમ͜٫ɓߧdઓમॶ˸ɨ׵͉ණྠ׵ 2020ϋ7˜1˚ක֐ʘϋܓಂග͛ࣖʘอ ࠈʿ຾ࡌࠈ࠰ಥৌਕజѓ๟ۆ€˜࠰ಥৌ ਕజѓ๟ۆ™ৰ̮f

• • Amendments to HKFRS 3, Definition of a Business

  • • ࠰ಥৌਕజѓ๟ۆୋ3໮ ʘ ࡌ ࠈุ ਕʘ່֛

• • Amendment to HKFRS 16, Covid-19-Related Rent Concessions

• • ࠰ಥৌਕజѓ๟ۆୋ16໮ʘࡌࠈ อۨڿًषݭषʘ޴ᗫॡږಯе

• (a) Corporate healthcare solution services ("Corporate Healthcare Solution Services to Contract Customers") segment engages in the provision of corporate healthcare solutions to contract customers; and

  • (a) Άุᔼᐕڭ਄༆Ӕ˙ࣩ؂ਕ€˜Σ Υߒ܄˒౤ԶΆุᔼᐕڭ਄༆Ӕ ˙ࣩ؂ਕ™ʱ௅މΥߒ܄˒౤Զ Άุᔼᐕڭ਄༆Ӕ˙ࣩiʿ

• (b) Clinical healthcare services ("Clinical Healthcare Services") segment engages in the provision of medical and dental services, health check-up and other auxiliary services.

• (b) ᑗґᔼᐕڭ਄؂ਕ€˜ᑗґᔼᐕڭ ਄؂ਕ™ܼ̍౤Զᔼᐕʿ˫߅؂ ਕe਄ੰᏨݟʿՉ˼Ⴞп؂ਕf

OPERATING SEGMENT INFORMATION

(Continued)

(a) Revenue and results

Six months ended 31

December 2020 (unaudited)

Segment revenue (note 5):

External sales Inter-segment sales

Reconciliation:

Elimination of inter-segment sales

Revenue

Segment results Reconciliation: Interest income

Other income and gains Share of profits and losses of:

Joint ventures

Associates Corporate and other unallocated expenses, net Profit before tax

4. 經營分部資料€ᚃ

(a) 收入及業績

Corporate Healthcare

Solution

Services to

Contract Customers 向合約客戶 提供企業 醫療保健 解決方案服務

HK$'000 千港元

Clinical Healthcare

Services

臨床醫療 保健服務

HK$'000 千港元

Total

合計

HK$'000 千港元

4. OPERATING SEGMENT INFORMATION

(Continued)

(a) Revenue and results (Continued)

Six months ended 31

December 2019 (unaudited)

截至2019年12月31日止 六個月（未經審核）

4. 經營分部資料€ᚃ

(a) 收入及業績€ᚃ

Corporate

Healthcare

Solution

Services to

Contract Customers

ΣΥߒ܄˒

౤ԶΆุ ᔼᐕڭ਄ ༆Ӕ˙ࣩ؂ਕ

HK$'000 ɷಥʩ

Clinical Healthcare

Services

ᑗґᔼᐕ ڭ਄؂ਕ

HK$'000 ɷಥʩ

Total

Υࠇ

HK$'000 ɷಥʩ

Segment revenue (note 5):

External sales Inter-segment sales

分部收入（附註 5）： ̮௅ቖਯ ʱ௅ගቖਯ

Reconciliation:

Elimination of inter-segment sales

Revenue

Segment results Reconciliation: Interest income

Other income and gains Share of profits and losses of:

Joint ventures

Associates Corporate and other unallocated expenses, net Profit before tax

ሜືj ʱ௅ගቖਯתቖ

132,418 174,395 306,813

791 133,209

51,640 52,431 226,035 359,244

ϗɝ

(52,431) 306,813

分部業績 ሜືj

21,927

30,902 52,829

лࢹϗɝ 3,054

Չ˼ϗɝʿϗू 7,868 ʱЦлᆗʿᑦฦj

Υ༟ʮ̡ (169)

ᑌᐄʮ̡ 967 ʮ̡ʿՉ˼͊ʱৣ

ක˕ଋᕘ ৰ೼ۃлᆗ

(6,245) 58,304

• 4. OPERATING SEGMENT INFORMATION

  (Continued)

  (b) Information about major customers

  Revenue from a major customer which accounted for

  10% or more of the Group's revenue from the Corporate

  Healthcare Solution Services to Contract Customers

  segment is set out below:

  Customer A

  4. 經營分部資料€ᚃ

  (b) 主要客戶資料

  ԸІɓΤ˴ࠅ܄˒€Ц͉ණྠԸІ ΣΥߒ܄˒౤ԶΆุᔼᐕڭ਄༆ Ӕ˙ࣩ؂ਕʱ௅ٙϗɝٙ10%א˸ ɪٙ܄˒ٙϗɝ༱ΐνɨj

  Six months ended 31 December 截至12月31日止六個月

  ܄˒A

  2020	2019
  2020年	2019ϋ
  HK$'000	HK$'000
  千港元	ɷಥʩ
  (Unaudited)	(Unaudited)
  （未經審核）	€͊຾ᄲࣨ
  20,654	22,095

• 5. REVENUE, OTHER INCOME AND GAINS

  An analysis of revenue is as follows:

Revenue from contracts with customers

Provision of corporate healthcare solution services:

Medical services Dental services

Provision of clinical healthcare services:

Medical services

Dental services

5. 收入、其他收入及收益

ϗɝʘʱؓνɨj

Six months ended 31 December 截至12月31日止六個月

2020 2020年 HK$'000 千港元

(Unaudited)

（未經審核）

2019 2019ϋ HK$'000 ɷಥʩ

(Unaudited)

€͊຾ᄲࣨ

SegmentsType of services

Medical services Dental services

Total revenue from contracts with customers

Geographical markets

Hong Kong and Macau PRC

Total revenue from contracts with customers

分部

Contract Customers 向合約客戶 提供企業 醫療保健 解決方案服務

5.

Solution Services to

HK$'000 千港元

Clinical Healthcare

Services

臨床醫療 保健服務

HK$'000 千港元

Total

合計

HK$'000 千港元

Segments

ʱ௅

Type of services

Medical services

Dental services

Total revenue from contracts with customers

服務類型 ᔼᐕ؂ਕ ˫߅؂ਕ ܄˒Υߒϗɝᐼᕘ

Geographical markets

Hong Kong and Macau